



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India,
Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority
ORDER

New Delhi, the 1st April 2017

S.O. 1051 (E)- In exercise of powers, conferred by sub paragraph (3) and (4) of paragraph 11 and paragraph 14 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013, S.O. 1192(E) dated 22nd March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers and in supersession of the order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O 1993(E) dated 3rd June, 2016 read with Corrigendum order S.O 2062 dated 9th June, 2016, S.O 2210(E) dated 24th June 2016, S.O 2578(E) dated 1st August 2016, S.O. 3161(E) dated 6th October 2016 in so far as they relate to formulation packs of Non-Glass with special features (mentioned as Non-PVC in S.O. 1993(E) dated 3rd June 2016) mentioned in the **Table A** herein below, manufactured by the manufacturers specified in **Table B** for specified products and pack-sizes, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby revises the price based on Wholesale price index(WPI) of 2016 as specified in column (5) of the **Table A** herein below as separate ceiling price exclusive of local tax applicable, if any in respect of the scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form and strength and unit/packaging specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table A: Price Revision as per Annual Wholesale Price Index (WPI) @ 1.97186% increase.

SI No	Medicines	Dosage form and Strength	Unit/packaging	Ceiling price (wef 01.4.2017 with WPI @ 1.97186%)
(1)	(2)	(3)	(4)	(5)
1	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	1000ml Non Glass with special features	75.96
2	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	500ml Non Glass with special features	64.99
3	Glucose	Injection 5%	1000ml Non Glass with special features	72.28
4	Glucose	Injection 5%	500ml Non Glass with special features	62.53
5	Sodium Chloride	Injection 0.9%	1000ml Non Glass with special features	74.86
6	Sodium Chloride	Injection 0.9%	100ml Non Glass with special features	31.97
7	Sodium Chloride	Injection 0.9%	250ml Non Glass with special features	47.19
8	Sodium Chloride	Injection 0.9%	500ml Non Glass with special features	66.84

TABLE 'B'

Sl. No.	Name of Manufacturer	Product /Brand Name
---------	----------------------	---------------------



(1)	(2)	(3)
1	M/s B.Braun Medical (I) Pvt Ltd.	Ecoflac Plus bottle with Eurohead
2	M/s Amanta Healthcare Ltd.	Steriport bottle
3	M/s Aculife Healthcare Pvt Ltd.	Aculife bottle with Eurohead

4	M/s Albert David Limited	Albert David bottle with Eurohead
5	M/s Denis Chem Limited	Aquapulse with Eurohead
6	M/s Claris Life Sciences Limited	Claris bottle with Eurohead
7	M/s Fresenius Kabi India Pvt Limited	Freeflex bags
8	M/s Otsuka Pharmaceutical India Private Ltd. (previously known as Claris Otsuka Private Limited)	Unibag
9	M/s Aishwarya Lifesciences	Lifusion Eurohead bottle
10	M/s Baxter (India) Pvt. Ltd.	Viaflex bags
11	M/s Claris Otsuka Private Limited	Eurohead bottle
12	M/s Fresenius Kabi India Pvt Limited	Eurohead bottle

- (a) The ceiling prices are applicable with effect from 01.4.2017 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 1.97186% for the year 2016 over 2015).
- (b) The manufacturers of scheduled formulations, selling abovesaid products/brandname of scheduled formulations at price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- (c) The manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus local taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 1.97186% for year 2016 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.
- (d) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (e) Any other manufacturer claiming separate ceiling price for Non-Glass with special feature shall apply to NPPA for separate ceiling price approval with details and demonstrate, that such pack has all of the features as (i) self collapsibility and self-sealability (ii) not having air-vent; and (iii) there is no chance of contamination during manufacture/ infusion/ admixing levels alongwith documentation and demonstration.
- (f) For other special features claimed or any other pack size manufactured, the manufacturer shall approach the NPPA for specific price approval for its formulation
- (g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of



in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.

- (k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/175/43/2017/F

F. No. 8(43)/2017/D.P./NPPA-Div.II

(BALJIT SINGH)
Assistant Director
National Pharmaceutical Pricing Authority



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 1st April, 2017

ORDER

S.O 1040(E).In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 644(E), dated 2nd March, 2016, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table
Price Revision as per Annual Wholesale Price Index (WPI) @ 1.97186% increase

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.) w.e.f 01.4.2017
(1)	(2)	(3)	(4)	(5)
1.	Acetyl Salicylic Acid	Tablet 300mg	1 Tablet	0.21414
2.	Acetyl Salicylic Acid	Tablet 325mg	1 Tablet	0.74
3.	Actinomycin D	Injection 0.5mg	1 Injection	580.02
4.	Anti-D immunoglobulin (human)	Injection 300 µg	Each pack	2,420.57
5.	Antitetanus Human immunoglobulin	Injection 250 IU	Each Pack	1,034.87
6.	Antitetanus Human immunoglobulin	Injection 500 IU	Each Pack	1,725.16
7.	Ascorbic Acid	Tablet 100mg	1 Tablet	0.18355
8.	BCG Vaccine	Injection	Each Dose	5.74
9.	Calcium carbonate	Tablet 250 mg	1 Tablet	1.85
10.	Calcium carbonate	Tablet 500 mg	1 Tablet	1.84
11.	Calcium gluconate	Injection 100mg/ml in 10 ml ampoule	10 ML Ampoule	10.90
12.	Cloxacillin	Capsule 250mg	1 Capsule	1.33
13.	Cloxacillin	Capsule 500mg	1 Capsule	2.28
14.	Cloxacillin	Injection 250mg	Each Pack	5.70



15.	Condoms	--	1 Condom	8.28
16.	D.P.T Vaccine	Injection	1 Vial	255.07

17.	Dapsone	Tablet 50 mg	1 Tablet	0.21414
18.	Daunorubicin	Injection 20 mg	Each Pack	387.42
19.	Desferrioxamine mesylate	Injection 500mg	Each Pack	162.81
20.	Dextran-40	Injection 10%	1 ML	0.83
21.	Digoxin	Injection 0.25 mg/ml	1 ML	4.10
22.	Diloxanide Furoate	Tablet 500 mg	1 Tablet	1.76
23.	Diphtheria Antitoxin	Injection 10,000 IU	Each Pack	1,266.26
24.	Esmolol	Injection 10 mg/ml	1 ML	22.47
25.	Ethyl Alcohol 70% Solution	-	1 ML	0.54
26.	Etoposide	Capsules 100 mg	1 Capsule	57.29
27.	Filgrastim	Injection	1 ML	2,347.16
28.	Fluoxetine hydrochloride	Capsules 20 mg	1 Capsule	3.80
29.	Framycetin Sulphate	Cream 0.50%	1 GM	0.82
30.	Gentian Violet Paint	1%	1 ML	0.06182
31.	Glucose	Injection 10%	1 ML	0.05477
32.	Glutaraldehyde	Solution 2%	1 ML	0.09272
33.	Glyceryl Trinitrate	Injection 5mg/ml	1 ML	8.25
34.	Griseofulvin	Tablet 125mg	1 Tablet	0.77
35.	Heparin Sodium	Injection 1000 IU/ml	1 ML	19.18
36.	Heparin Sodium	Injection 5000IU/ml	1 ML	44.85
37.	Hepatitis B Vaccine	Injection	1 ML	110.73
38.	Hormone Releasing IUD	--	1 IUD	4,615.60
39.	Hydrogen Peroxide	Solution 6%	1 ML	0.05151
40.	Ifosfamide	Injection 1 gm/2ml vial	Each Pack	377.78
41.	Isoniazid	Tablet 100 mg	1 Tablet	0.80
42.	Isoniazid	Tablet 300 mg	1 Tablet	1.39
43.	Isoniazid	Syrup 100 mg/5ml	1 ML	0.23454
44.	IUD containing Copper	--	1 IUD	362.05

45.	Lignocaine Hydrochloride + Adrenaline	Injection 1%+Adrenaline 1:200,000	Each Pack	0.74
46.	Mannitol	Injection 10%	1 ML	0.24473
47.	Measles Vaccine	Injection	Each Pack	277.10
48.	Medroxy Progesterone Acetate	Tablet 5mg	1 Tablet	2.83
49.	Mercaptopurine	Tablet 50mg	1 Tablet	9.78
50.	Morphine Sulphate	Injection 10 mg / ml	1 ML	23.58
51.	Morphine Sulphate	Tablets 10 mg	1 Tablet	5.53
52.	Nitrous Oxide Inhalation	--	Cubic Meter	225.85
53.	Oral Poliomyelitis vaccine (LA)	Solution	1 ML	109.43
54.	Oxygen Inhalation	--	Cubic Meter	17.33
55.	Phenylephrine	Drops 5%	1 ML	5.10
56.	Phytomenadione	Injection 10 mg/ml	1 ML	48.00
57.	Potassium Permanganate	Crystals for Solution	1 GM	0.42
58.	Praziquantel	Tablet 600 mg	1 Tablet	26.16
59.	Prednisolone	Injection 20mg (as Sodium Phosphate or Succinate)	1 ML	4.65
60.	Pyridoxine	Tablet 10mg	1 Tablet	0.22434
61.	Ringer Lactate Injection	As per IP	1 ML	0.11332
62.	Sevoflurane Inhalation	--	1 ML	30.66
63.	Silver Sulphadiazine	Cream 1%	1 GM	0.48
64.	Sodium Nitrite	Injection 30mg/ml	1 ML	20.42
65.	Specific Antisnake Venom Injection Polyvalent Solution	--	1 ML	48.10
66.	Specific Antisnake Venom Lyophilized Polyvalent Serum	--	1 ML	58.40
67.	Vinblastine Sulphate	Injection 10mg	Each Pack	312.07
68.	Vitamin A	Capsule 50000 IU	1 Capsule	0.72

Note:

- (a) The ceiling prices are applicable with effect from 01.4.2017 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 1.97186% for the year 2016 over 2015).
- (b) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- (c) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus local taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 1.97186% for year 2016 in accordance with paragraph 16(2) of DPCO, 2013, subject to ceiling price (plus local taxes as applicable, if any).
- (d) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (e) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (f) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (g) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (h) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (i) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (j) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/175/43/2017/F

F. No. 8(43)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 1st April, 2017

ORDER

S.O. 1039(E) - In exercise of the powers, conferred by paragraph 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. No. 1394(E) dated the 30th May, 2013 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order(s) of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) S.O. Number and date specified in column no. 6(a) & 6(b) mentioned in the table below, the National Pharmaceutical Pricing Authority, hereby fixes the prices as specified in column (5) of the table herein below as ceiling prices exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

Table : Price Revision as per Annual Wholesale Price Index (WPI) @ 1.97186% increase.

SI No	Medicines	Dosage form and Strength	Unit	Ceiling price (wef 01.4.2017 with WPI @ 1.97186%)	Existing S.O. No. & Existing Date	
(1)	(2)	(3)	(4)	(5)	6(a)	6(b)
1	5-Fluorouracil	Injection 250 mg/5 ML	1 ML	2.13	4128(E)	22.12.2016
2	Abacavir	Tablet 300 mg	1 Tablet	44.62	1254(E)	29.3.2016
3	Abacavir (A) + Lamivudine (B)	Tablet 600 mg (A)+ 300 mg (B)	1 Tablet	86.22	1817(E)	18.5.2016
4	Acetazolamide	Capsule 250 mg	1 Capsule	4.11	3430(E)	10.11.2016
5	Acetazolamide	Tablet 250 mg	1 Tablet	3.32	2569(E)	29.7.2016
6	Acetylsalicylic acid	Effervescent/ Dispersible/ Enteric coated Tablet 150 mg	1 Tablet	1.14	1254(E)	29.3.2016
7	Acetylsalicylic acid	Effervescent/ Dispersible/ Enteric coated Tablet 75 mg	1 Tablet	1.16	1254(E)	29.3.2016
8	Acetylsalicylic acid	Tablet 150 mg	1 Tablet	0.39	1254(E)	29.3.2016
9	Acetylsalicylic acid	Tablet 75 mg	1 Tablet	0.29	443(E)	14.2.2017
10	Acetylsalicylic acid	Tablet 100 mg	1 Tablet	0.16865	788(E)	10.03.2017
11	Acyclovir	Ointment 3%	1 GM	9.85	1560(E)	27.4.2016
12	Acyclovir	Oral liquid 400 mg/5 ML	1 ML	1.20	4128(E)	22.12.2016
13	Acyclovir	Powder for Injection 500 mg	Each Pack	434.20	4128(E)	22.12.2016
14	Acyclovir	Powder for Injection 250 mg	Each Pack	336.18	4128(E)	22.12.2016

15	Acyclovir	Tablet 200 mg	1 Tablet	6.41	2195(E)	23.6.2016
16	Acyclovir	Tablet 400 mg	1 Tablet	11.65	2195(E)	23.6.2016
17	Adenosine	Injection 3 mg/ML	1 ML	84.38	443(E)	14.2.2017
18	Adrenaline	Injection 1 mg/ML	1 ML	12.57	3181(E)	7.10.2016
19	Albendazole	Oral Liquid 200mg/5ML	1 ML	1.51	248(E)	24.01.2017
20	Albendazole	Tablet 400 mg	1 Tablet	7.29	2195(E)	23.6.2016
21	Allopurinol	Tablet 100mg	1 Tablet	1.79	1951(E)	2.6.2016
22	Allopurinol	Tablet 300 mg	1 Tablet	7.08	1254(E)	29.3.2016
23	Alprostadil	Injection 0.5 mg/ML	1 ML	5,358.16	1560(E)	27.4.2016
24	Amiodarone	Tablet 200 mg	1 Tablet	10.72	1819(E)	18.5.2016
25	Amiodarone	Injection 50 mg/ML	1 ML	18.55	443(E)	14.2.2017
26	Amiodarone	Tablet 100 mg	1 Tablet	5.40	2195(E)	23.6.2016
27	Amitriptyline	Tablet 50 mg	1 Tablet	5.50	1404(E)	12.4.2016
28	Amitriptyline	Tablet 25 mg	1 Tablet	2.14	2195(E)	23.6.2016
29	Amitriptyline	Tablet 75 mg	1 Tablet	5.31	1404(E)	12.4.2016
30	Amitriptyline	Tablet 10 mg	1 Tablet	2.17	1404(E)	12.4.2016
31	Amlodipine	Tablet 5mg	1 Tablet	2.38	1686(E)	9.5.2016
32	Amlodipine	Tablet 10 mg	1 Tablet	4.80	1254(E)	29.3.2016
33	Amlodipine	Tablet 2.5 mg	1 Tablet	1.56	2195(E)	23.6.2016
34	Amoxicillin	Capsule 500 mg	1 Capsule	5.81	1819(E)	18.5.2016
35	Amoxicillin	Capsule 250mg	1 Capsule	2.09	1951(E)	2.6.2016
36	Amoxicillin	Oral liquid 250 mg/5 ML	1 ML	1.28	1560(E)	27.4.2016
37	Amoxicillin (A) + Clavulanic acid (B)	Powder for injection 1GM (A) +200mg (B)	Each Pack	116.16	1819(E)	18.5.2016
38	Amoxicillin (A) + Clavulanic acid (B)	Dry Syrup 125 mg (A) + 31.25 (B)/5 ML	1 ML	2.04	1560(E)	27.4.2016
39	Amoxicillin (A) + Clavulanic acid (B)	Oral Liquid 200mg (A) + 28.5mg (B)/5ML	1 ML	1.71	1951(E)	2.6.2016
40	Amoxicillin (A) + Clavulanic acid (B)	Powder for Injection 500 mg (A) + 100 mg (B)	Each Pack	85.18	4128(E)	22.12.2016
41	Amoxicillin (A) + Clavulanic acid (B)	Tablet 500 mg (A) + 125 mg (B)	1 Tablet	16.46	1819(E)	18.5.2016
42	Amphotericin B – Conventional	Powder for Injection 50 mg	Each Pack	281.05	788(E)	10.03.2017
43	Amphotericin B – Lipid/ Liposomal	Powder for Injection 50 mg	Each Pack	3,394.25	788(E)	10.03.2017
44	Ampicillin	Powder for Injection 1 GM	Each Pack	20.20	1404(E)	12.4.2016
45	Ampicillin	Powder for Injection 500 mg	Each Pack	12.44	4128(E)	22.12.2016
46	Artemether (A) + Lumefantrine (B)	Tablet 20 mg (A) + 120 mg (B)	1 Tablet	11.85	1254(E)	29.3.2016
47	Artemether (A) + Lumefantrine (B)	Tablet 40 mg (A) + 240 mg (B)	1 Tablet	15.27	1254(E)	29.3.2016
48	Artemether (A) + Lumefantrine (B)	Tablet 80 mg (A) + 480 mg (B)	1 Tablet	21.92	1254(E)	29.3.2016
49	Artesunate	Powder for Injection 120 mg	Each Pack	377.59	1404(E)	12.4.2016
50	Artesunate	Powder for Injection 60 mg	Each Pack	198.33	1404(E)	12.4.2016
51	Artesunate (A) + Sulphadoxine -	1 Tablet 50 mg (A)	Combi Pack	20.08	3431(E)	10.11.2016

	Pyrimethamine (B)	+ 1 Tablet (500 mg + 25 mg) (B)				
52	Ascorbic Acid (Vitamin C)	Tablet 500mg	1 Tablet	0.86	4129(E)	22.12.2016
53	Atazanavir (A) + Ritonavir (B)	Tablet 300 mg (A) + 100 mg (B)	1 Tablet	93.41	1254(E)	29.3.2016
54	Atenolol	Tablet 100mg	1 Tablet	3.30	2569(E)	29.7.2016
55	Atenolol	Tablet 50 mg	1 Tablet	1.69	2195(E)	23.6.2016
56	Atorvastatin	Tablet 40 mg	1 Tablet	18.26	1254(E)	29.3.2016
57	Atorvastatin	Tablet 10 mg	1 Tablet	5.19	1254(E)	29.3.2016
58	Atorvastatin	Tablet 20 mg	1 Tablet	12.58	1254(E)	29.3.2016
59	Atracurium	Injection 10 mg/ML	Each Pack	49.59	4128(E)	22.12.2016
60	Atropine	Injection 0.6mg/ML	1 ML	3.80	2730(E)	17.8.2016
61	Atropine	Ointment 1%	1 GM	3.43	4128(E)	22.12.2016
62	Atropine	Drops 1%	1 ML	3.11	3431(E)	10.11.2016
63	Azathioprine	Tablet 50mg	1 Tablet	9.20	1951(E)	2.6.2016
64	Azithromycin	Capsule 250 mg	1 Capsule	9.94	3180(E)	7.10.2016
65	Azithromycin	Capsule 500 mg	1 Capsule	15.68	3180(E)	7.10.2016
66	Azithromycin	Oral Liquid 200mg/5ML	1 ML	2.91	1687(E)	9.5.2016
67	Azithromycin	Powder for Injection 500 mg	Each Pack	180.39	4128(E)	22.12.2016
68	Baclofen	Tablet 10 mg	1 Tablet	9.75	1254(E)	29.3.2016
69	Baclofen	Tablet 20 mg	1 Tablet	13.43	1254(E)	29.3.2016
70	Baclofen	Tablet 5 mg	1 Tablet	5.03	1254(E)	29.3.2016
71	Benzathine benzylpenicillin	Powder for Injection 12 lac units	Each Pack	11.49	4128(E)	22.12.2016
72	Benzathine benzylpenicillin	Powder for Injection 6 lac units	Each Pack	7.61	4128(E)	22.12.2016
73	Benzoyl Peroxide	Cream 2.5%	1 GM	2.22	3430(E)	10.11.2016
74	Benzoyl Peroxide	Gel 2.5%	1 GM	3.55	1560(E)	27.4.2016
75	Betamethasone	Cream 0.05%	1 GM	0.55	3431(E)	10.11.2016
76	Betamethasone	Gel 0.05%	1 GM	0.50	247(E)	24.01.2017
77	Betamethasone	Injection 4 mg/ML	1 ML	3.97	3431(E)	10.11.2016
78	Bicalutamide	Tablet 50 mg	1 Tablet	64.91	1404(E)	12.4.2016
79	Bisacodyl	Suppository 5mg	1 Suppository	7.98	248(E)	24.01.2017
80	Bisacodyl	Tablet 5mg	1 Tablet	0.95	1951(E)	2.6.2016
81	Bleomycin	Powder for Injection 15 Units	Each Pack	563.26	3181(E)	7.10.2016
82	Bortezomib	Powder for Injection 2mg	Each Pack	11,636.60	1404(E)	12.4.2016
83	Budesonide	Inhalation (MDI/DPI) 100 mcg/dose	1 Dose	1.24	1560(E)	27.4.2016
84	Budesonide	Inhalation (MDI/DPI) 200 mcg/dose	1 Dose	1.53	1560(E)	27.4.2016
85	Budesonide	Respiratory Solution for use in Nebulizer 0.5mg/ML	1 ML	10.13	1560(E)	27.4.2016
86	Budesonide	Respiratory Solution for use in Nebulizer 1mg/ML	1 ML	12.22	1560(E)	27.4.2016
87	Budesonide (A)+ Formoterol (B)	Inhalation (MDI/DPI) 400 mcg (A) + 6 mcg (B)	1 Dose	2.79	1560(E)	27.4.2016

88	Budesonide (A)+ Formoterol (B)	Inhalation (MDI/DPI) 200 mcg (A) + 6 mcg (B)	1 Dose	2.23	1560(E)	27.4.2016
89	Budesonide (A)+ Formoterol (B)	Inhalation (MDI/DPI) 100 mcg (A) + 6 mcg (B)	1 Dose	1.77	1560(E)	27.4.2016
90	Bupivacaine	Injection 0.25%	1 ML	2.31	3181(E)	7.10.2016
91	Bupivacaine	Injection 0.50%	1 ML	3.71	3181(E)	7.10.2016
92	Bupivacaine	Injection 0.5% with 7.5% glucose	1 ML	5.88	788(E)	10.03.2017
93	Caffeine	Injection 20 mg/ML	1 ML	237.48	1560(E)	27.4.2016
94	Caffeine	Oral Liquid 20mg/ML	1 ML	201.70	1687(E)	9.5.2016
95	Calamine	Lotion (As per IP)	1 ML	0.80	788(E)	10.03.2017
96	Calcium folinate	Tablet 15 mg	1 Tablet	37.02	1404(E)	12.4.2016
97	Capecitabine	Tablet 500 mg	1 Tablet	119.58	1560(E)	27.4.2016
98	Capreomycin	Powder for Injection 1 GM	Each Pack	327.72	1404(E)	12.4.2016
99	Carbamazepine	Tablet 100 mg	1 Tablet	0.65	2963(E)	15.09.2016
100	Carbamazepine	CR Tablet 400 mg	1 Tablet	2.89	1254(E)	29.3.2016
101	Carbamazepine	CR Tablet 200 mg	1 Tablet	1.47	1254(E)	29.3.2016
102	Carbamazepine	Oral Liquid 100mg/5 ML	1 ML	0.18355	2730(E)	17.8.2016
103	Carbamazepine	Tablet 400 mg	1 Tablet	3.13	1254(E)	29.3.2016
104	Carbamazepine	Tablet 200 mg	1 Tablet	1.31	2195(E)	23.6.2016
105	Carbimazole	Tablet 10mg	1 Tablet	3.49	1819(E)	18.5.2016
106	Carbimazole	Tablet 5mg	1 Tablet	1.79	1951(E)	2.6.2016
107	Carboplatin	Injection 10 mg/ML	1 ML	50.35	1561 (E)	27.4.2016
108	Carboxymethylcellulose	Drops 0.5%	1 ML	12.08	3432(E)	10.11.2016
109	Carboxymethylcellulose	Drops 1%	1 ML	16.76	3432(E)	10.11.2016
110	Cefadroxil	Tablet 1 GM	1 Tablet	5.94	2962(E)	15.09.2016
111	Cefadroxil	Capsule 500mg	1 Capsule	6.77	1687(E)	9.5.2016
112	Cefadroxil	Oral liquid 125 mg/5 ML	1 ML	0.59	1560(E)	27.4.2016
113	Cefadroxil	Tablet 500 mg	1 Tablet	3.82	1254(E)	29.3.2016
114	Cefazolin	Powder for Injection 1 GM	Each Pack	23.23	1404(E)	12.4.2016
115	Cefazolin	Powder for injection 500 mg	Each Pack	14.72	2962(E)	15.09.2016
116	Cefixime	Capsule 400 mg	1 Capsule	27.66	4127(E)	22.12.2016
117	Cefixime	Capsule 200 mg	1 Capsule	13.65	247(E)	24.01.2017
118	Cefixime	Oral liquid 100 mg/5 ML	1 ML	2.03	1687(E)	9.5.2016
119	Cefixime	Oral liquid 50 mg/5 ML	1 ML	1.37	1687(E)	9.5.2016
120	Cefixime	Tablet 200 mg	1 Tablet	8.65	1819(E)	18.5.2016
121	Cefixime	Tablet 400 mg	1 Tablet	20.88	1254(E)	29.3.2016
122	Cefotaxime	Powder for Injection 500 mg	Each Pack	19.42	443(E)	14.2.2017
123	Cefotaxime	Powder for Injection 250 mg	Each Pack	14.76	443(E)	14.2.2017
124	Cefotaxime	Powder for Injection 1 GM	Each Pack	32.48	1817(E)	18.5.2016
125	Ceftazidime	Powder for Injection 250 mg	Each Pack	61.58	3431(E)	10.11.2016
126	Ceftazidime	Powder for Injection 1GM	Each Pack	198.02	3431(E)	10.11.2016



127	Ceftriaxone	Powder for Injection 2 GM	Each Pack	121.24	1404(E)	12.4.2016
128	Ceftriaxone	Powder for Injection 500 mg	Each Pack	42.65	1404(E)	12.4.2016
129	Ceftriaxone	Powder for Injection 1GM	Each Pack	48.90	1686(E)	9.5.2016
130	Ceftriaxone	Powder For Injection 250mg	Each Pack	23.35	1951(E)	2.6.2016
131	Cetirizine	Tablet 10mg	1 Tablet	1.56	1951(E)	2.6.2016
132	Cetirizine	Capsule 10mg	1 Capsule	2.25	247(E)	24.01.2017
133	Cetirizine	Oral liquid 5 mg/5 ML	1 ML	0.56	1687(E)	9.5.2016
134	Cetrimide	Solution 20% (concentrate for dilution)	1 ML	0.30	3431(E)	10.11.2016
135	Chlorambucil	Tablet 5 mg	1 Tablet	75.26	1404(E)	12.4.2016
136	Chlorambucil	Tablet 2mg	1 Tablet	33.49	2569(E)	29.7.2016
137	Chloroquine	Oral Liquid 50 mg/5 ML	1 ML	0.27	443(E)	14.2.2017
138	Chloroquine	Tablet 150mg	1 Tablet	0.60	443(E)	14.2.2017
139	Chlorpheniramine	Tablet 4mg	1 Tablet	0.08682	2569(E)	29.7.2016
140	Cholecalciferol	Tablet 60000 IU	1 Tablet	22.94	2964(E)	15.9.2016
141	Cholecalciferol	Capsule 1000 IU	1 Capsule	4.51	1687(E)	9.5.2016
142	Cholecalciferol	Capsule 60000 IU	1 Capsule	27.94	2964(E)	15.9.2016
143	Cholecalciferol	Oral liquid 400 IU/ML	1 ML	2.23	1687(E)	9.5.2016
144	Cholecalciferol	Tablet 1000 IU	1 Tablet	3.55	1254(E)	29.3.2016
145	Ciprofloxacin	Injection 200mg/100ML	1 ML	0.15968	443(E)	14.2.2017
146	Ciprofloxacin	Drops 0.30%	1 ML	1.44	443(E)	14.2.2017
147	Ciprofloxacin	Tablet 250 mg	1 Tablet	1.65	1686(E)	9.5.2016
148	Ciprofloxacin	Tablet 500 mg	1 Tablet	3.37	1686(E)	9.5.2016
149	Ciprofloxacin	Ointment 0.3%	1 GM	1.06	3431(E)	10.11.2016
150	Cisplatin	Injection 1mg /ML	1 ML	6.52	1561(E)	27.4.2016
151	Clarithromycin	Oral liquid 125mg/5 ML	1 ML	4.09	1560(E)	27.4.2016
152	Clarithromycin	Tablet 250 mg	1 Tablet	26.49	1254(E)	29.3.2016
153	Clarithromycin	Tablet 500 mg	1 Tablet	46.69	1254(E)	29.3.2016
154	Clindamycin	Capsule 300 mg	1 Capsule	21.43	1254(E)	29.3.2016
155	Clindamycin	Capsule 150 mg	1 Capsule	13.13	1254(E)	29.3.2016
156	Clindamycin	Tablet 300mg	1 Tablet	13.83	1686(E)	9.5.2016
157	Clobazam	Tablet 5 mg	1 Tablet	4.86	1254(E)	29.3.2016
158	Clobazam	Tablet 10 mg	1 Tablet	8.55	1254(E)	29.3.2016
159	Clofazimine	Capsule 100mg	1 Capsule	2.24	2569(E)	29.7.2016
160	Clofazimine	Capsule 50mg	1 Capsule	1.31	2569(E)	29.7.2016
161	Clomiphene	Capsule 100 mg	1 Capsule	52.66	3430(E)	10.11.2016
162	Clomiphene	Tablet 50mg	1 Tablet	7.05	443(E)	14.2.2017
163	Clomiphene	Tablet 100mg	1 Tablet	11.07	443(E)	14.2.2017
164	Clomipramine	Tablet 75mg	1 Tablet	13.58	1687(E)	9.5.2016
165	Clomipramine	Tablet 25mg	1 Tablet	5.25	1687(E)	9.5.2016
166	Clomipramine	Tablet 10mg	1 Tablet	2.38	1687(E)	9.5.2016
167	Clonazepam	Tablet 0.5 mg	1 Tablet	2.94	1404(E)	12.4.2016
168	Clonazepam	Tablet 0.25 mg	1 Tablet	1.73	1404(E)	12.4.2016
169	Clonazepam	Tablet 1 mg	1 Tablet	4.00	1404(E)	12.4.2016
170	Clopidogrel	Tablet 75 mg	1 Tablet	6.57	1686(E)	9.5.2016
171	Clotrimazole	Cream 1%	1 GM	2.40	1687(E)	9.5.2016

172	Clotrimazole	Drop 1%	1 ML	2.87	1687(E)	9.5.2016
173	Clotrimazole	Pessary 100mg	1 Pessary	8.22	248(E)	24.01.2017
174	Clozapine	Tablet 100 mg	1 Tablet	7.33	1404(E)	12.4.2016
175	Clozapine	Tablet 25 mg	1 Tablet	2.38	1404(E)	12.4.2016
176	Clozapine	Tablet 50 mg	1 Tablet	4.55	1404(E)	12.4.2016
177	Coagulation factor VIII	Powder for Injection 250 IU	Each pack	3,389.14	1404(E)	12.4.2016
178	Colchicine	Tablet 0.5 mg	1 Tablet	2.94	2569(E)	29.7.2016
179	Co-trimoxazole (Sulphamethoxazole (A)+Trimethoprim (B))	Tablet 800mg (A)+160mg (B)	1 Tablet	1.00	443(E)	14.2.2017
180	Co-trimoxazole (Sulphamethoxazole (A)+Trimethoprim (B))	Oral Liquid 200mg (A)+40mg (B)/5ML	1 ML	0.20394	443(E)	14.2.2017
181	Co-trimoxazole (Sulphamethoxazole (A)+Trimethoprim (B))	Tablet 400mg (A)+80mg (B)	1 Tablet	0.49	443(E)	14.2.2017
182	Cyclophosphamide	Powder for Injection 500 mg	Each Pack	72.42	3181(E)	7.10.2016
183	Cyclophosphamide	Tablet 50 mg	1 Tablet	3.68	2569(E)	29.7.2016
184	Cycloserine	Tablet 250mg	1 Tablet	44.16	1687(E)	9.5.2016
185	Cycloserine	Capsule 250 mg	1 Capsule	51.37	1254(E)	29.3.2016
186	Cyclosporine	Capsule 50 mg	1 Capsule	47.77	2195(E)	23.6.2016
187	Cyclosporine	Capsule 100 mg	1 Capsule	93.01	2195(E)	23.6.2016
188	Cyclosporine	Capsule 25 mg	1 Capsule	24.96	2963(E)	15.09.2016
189	Cyclosporine	Oral liquid 100 mg/ML	1 ML	85.77	2731(E)	17.8.2016
190	Cytosine arabinoside	Injection 100 mg/ML	Each Pack	180.27	4128(E)	22.12.2016
191	Cytosine arabinoside	Powder for Injection 500 mg	Each Pack	464.71	4128(E)	22.12.2016
192	Cytosine arabinoside	Powder for Injection 1000 mg	Each Pack	972.31	443(E)	14.2.2017
193	Dacarbazine	Powder for Injection 200 mg	Each Pack	415.65	1404(E)	12.4.2016
194	Dacarbazine	Powder for Injection 500 mg	Each Pack	937.67	3181(E)	7.10.2016
195	Darunavir	Tablet 600 mg	1 Tablet	157.93	1254(E)	29.3.2016
196	Dexamethasone	Injection 4mg/ML	Each Pack (10ML)	13.03	248(E)	24.01.2017
197	Dexamethasone	Injection 4mg/ML	Each Pack (30ML)	33.38	248(E)	24.01.2017
198	Dexamethasone	Injection 4mg/ML	Each Pack (20ML)	24.97	248(E)	24.01.2017
199	Dexamethasone	Injection 4mg/ML	Each Pack (2ML)	5.38	248(E)	24.01.2017
200	Dexamethasone	Tablet 0.5mg	1 Tablet	0.18355	1819(E)	18.5.2016
201	Diazepam	Injection 5mg/ML	1 ML	5.73	3181(E)	7.10.2016
202	Diazepam	Oral liquid 2 mg/5 ML	1 ML	2.59	4127(E)	22.12.2016
203	Diazepam	suppository 5 mg	1 Suppository	5.65	2730(E)	17.8.2016
204	Diazepam	Tablet 5 mg	1 Tablet	1.35	2569(E)	29.7.2016
205	Diazepam	Tablet 2mg	1 Tablet	1.42	2569(E)	29.7.2016
206	Diclofenac	Injection 25mg/ML	1 ML	1.38	4128(E)	22.12.2016
207	Diclofenac	Tablet 50mg	1 Tablet	1.80	1951(E)	2.6.2016
208	Dicyclomine	Injection 10 mg/ML	1 ML	2.49	3431(E)	10.11.2016
209	Diethylcarbamazine	Oral liquid 120 mg/5 ML	1 ML	0.44	1560(E)	27.4.2016
210	Diethylcarbamazine	Tablet 100 mg	1 Tablet	1.28	1254(E)	29.3.2016
211	Diethylcarbamazine	Tablet 50 mg	1 Tablet	0.51	2195(E)	23.6.2016
212	Digoxin	Tablet 0.25mg	1 Tablet	1.13	1819(E)	18.5.2016

213	Diltiazem	Capsule 90mg	1 Capsule	9.09	1687(E)	9.5.2016
214	Diltiazem	Injection 5 mg/ML	1 ML	2.98	4128(E)	22.12.2016
215	Diltiazem	SR Tablet 90 mg	1 Tablet	8.83	1254(E)	29.3.2016
216	Diltiazem	Tablet 30 mg	1 Tablet	2.27	2195(E)	23.6.2016
217	Diltiazem	Tablet 60 mg	1 Tablet	4.62	2195(E)	23.6.2016
218	Dinoprostone	Gel 0.5 mg	1 GM	76.69	1560(E)	27.4.2016
219	Dobutamine	Injection 50mg/ML	Each Pack	35.48	4128(E)	22.12.2016
220	Docetaxel	Powder for Injection 80 mg	Each Pack	10,767.88	1404(E)	12.4.2016
221	Docetaxel	Powder for Injection 20 mg	Each Pack	2,832.12	1404(E)	12.4.2016
222	Domperidone	Tablet 10 mg	1 Tablet	2.28	2195(E)	23.6.2016
223	Domperidone	Oral Liquid 1mg/ML	1 ML	1.02	4128(E)	22.12.2016
224	Donepezil	Tablet 10 mg	1 Tablet	15.18	1254(E)	29.3.2016
225	Donepezil	Tablet 5 mg	1 Tablet	10.64	1254(E)	29.3.2016
226	Dopamine	Injection 40mg/ML	1 ML	5.12	4128(E)	22.12.2016
227	Doxorubicin	Injection 2mg/ML	1 ML	33.97	1686(E)	9.5.2016
228	Doxycycline	Capsule 100mg	1 Capsule	2.37	2568(E)	29.7.2016
229	Doxycycline	Tablet 100 mg	1 Tablet	0.92	3181(E)	7.10.2016
230	Efavirenz	Capsule 200 mg	1 Capsule	21.85	3431(E)	10.11.2016
231	Efavirenz	Capsule 600 mg	1 Capsule	56.91	3431(E)	10.11.2016
232	Efavirenz	Tablet 200 mg	1 Tablet	20.57	3430(E)	10.11.2016
233	Efavirenz	Tablet 600 mg	1 Tablet	64.44	2729(E)	17.8.2016
234	Enalapril	Tablet 2.5 mg	1 Tablet	1.82	2195(E)	23.6.2016
235	Enalapril	Tablet 5 mg	1 Tablet	3.03	2195(E)	23.6.2016
236	Enoxaparin	Injection 40mg/0.4ML	0.1 ML	92.24	2963(E)	15.09.2016
237	Enoxaparin	Injection 60mg/0.6ML	0.1 ML	92.24	2963(E)	15.09.2016
238	Entecavir	Tablet 0.5 mg	1 Tablet	72.40	1254(E)	29.3.2016
239	Entecavir	Tablet 1 mg	1 Tablet	115.03	1254(E)	29.3.2016
240	Erythropoietin	Injection 10000 IU/ML	Each pack	2,396.09	1404(E)	12.4.2016
241	Erythropoietin	Injection 2000 IU/ML	Each pack	573.58	1404(E)	12.4.2016
242	Escitalopram	Tablet 10 mg	1 Tablet	7.67	1404(E)	12.4.2016
243	Escitalopram	Tablet 20 mg	1 Tablet	12.11	1404(E)	12.4.2016
244	Escitalopram	Tablet 5 mg	1 Tablet	4.33	1404(E)	12.4.2016
245	Ethambutol	Tablet 800 mg	1 Tablet	3.84	2195(E)	23.6.2016
246	Ethambutol	Tablet 600mg	1 Tablet	3.21	2569(E)	29.7.2016
247	Ethambutol	Tablet 400mg	1 Tablet	2.18	2569(E)	29.7.2016
248	Ethambutol	Tablet 200 mg	1 Tablet	0.96	2569(E)	29.7.2016
249	Ethinylestradiol	Tablet 0.05 mg	1 Tablet	3.40	4128(E)	22.12.2016
250	Ethinylestradiol	Tablet 0.01mg	1 Tablet	2.14	2569(E)	29.7.2016
251	Ethinylestradiol (A) + Levonorgestrel (B)	Tablet 0.03mg (A) + 0.15mg (B)	1 Tablet	3.13	1951(E)	2.6.2016
252	Ethionamide	Tablet 250 mg	1 Tablet	14.94	1254(E)	29.3.2016
253	Etoposide	Injection 20 mg/ML	1 ML	33.92	4128(E)	22.12.2016
254	Fentanyl	Injection 50mcg/ML	1 ML	21.48	4128(E)	22.12.2016
255	Filgrastim	Injection 300 mcg	Each pack	1,298.39	1404(E)	12.4.2016
256	Fluconazole	Capsule 100 mg	1 Capsule	23.90	3431(E)	10.11.2016
257	Fluconazole	Capsule 200 mg	1 Capsule	34.54	3431(E)	10.11.2016
258	Fluconazole	Injection 200 mg /100 ML	Each Pack	100.69	1404(E)	12.4.2016
259	Fluconazole	Tablet 400 mg	1 Tablet	29.56	1254(E)	29.3.2016



260	Fluconazole	Tablet 200 mg	1 Tablet	17.77	2195(E)	23.6.2016
261	Fluconazole	Tablet 150mg	1 Tablet	11.21	1951(E)	2.6.2016
262	Fluconazole	Tablet 100mg	1 Tablet	7.55	2569(E)	29.7.2016
263	Flunarizine	Tablet 10 mg	1 Tablet	4.47	1254(E)	29.3.2016
264	Flunarizine	Tablet 5 mg	1 Tablet	2.61	1254(E)	29.3.2016
265	Fluoxetine	Tablet 10mg	1 Tablet	2.36	1687(E)	9.5.2016
266	Fluoxetine	Tablet 40mg	1 Tablet	5.05	1687(E)	9.5.2016
267	Fluoxetine	Tablet 20 mg	1 Tablet	3.75	3180(E)	7.10.2016
268	Fluoxetine	Capsule 10 mg	1 Capsule	2.82	1404(E)	12.4.2016
269	Fluoxetine	Capsule 40 mg	1 Capsule	5.24	1404(E)	12.4.2016
270	Fluoxetine	Capsule 60 mg	1 Capsule	9.26	1404(E)	12.4.2016
271	Fluoxetine	Capsule 20 mg	1 Capsule	3.45	2195(E)	23.6.2016
272	Fluoxetine	Tablet 60mg	1 Tablet	7.00	1687(E)	9.5.2016
273	Fluphenazine	Depot Injection 25 mg/ML	1 ML	47.34	1560(E)	27.4.2016
274	Folic Acid	Capsule 5 mg	1 Capsule	5.33	3430(E)	10.11.2016
275	Folic Acid	Tablet 5 mg	1 Tablet	1.31	1819(E)	18.5.2016
276	Furosemide	Injection 10 mg/ ML	Each Pack	1.03	788(E)	10.03.2017
277	Furosemide	Tablet 40 mg	1 Tablet	0.47	788(E)	10.03.2017
278	Fusidic acid	Cream 2%	1 GM	8.63	1560(E)	27.4.2016
279	Ganciclovir	Powder for Injection 500 mg	Each Pack	1,531.30	3180(E)	7.10.2016
280	Gefitinib	Tablet 250 mg	1 Tablet	405.52	1404(E)	12.4.2016
281	Gemcitabine	Powder for Injection 1 GM	Each Pack	5,019.49	1406(E)	12.4.2016
282	Gemcitabine	Powder for Injection 200 mg	Each Pack	1,090.42	443(E)	14.2.2017
283	Gentamicin	Injection 40mg/ML	Each Pack (10ML)	17.00	248(E)	24.01.2017
284	Gentamicin	Injection 40mg/ML	Each Pack (20ML)	25.77	248(E)	24.01.2017
285	Gentamicin	Injection 40mg/ML	Each Pack (2ML)	4.56	248(E)	24.01.2017
286	Gentamicin	Injection 40mg/ML	Each Pack (30ML)	28.20	248(E)	24.01.2017
287	Gentamicin	Drops 0.3%	1 ML	0.86	3431(E)	10.11.2016
288	Glimepiride	Tablet 2 mg	1 Tablet	5.39	1254(E)	29.3.2016
289	Glimepiride	Tablet 1 mg	1 Tablet	3.40	1254(E)	29.3.2016
290	Glucose	Injection 25%	1 ML	0.16268	4128(E)	22.12.2016
291	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	1000ML Glass	61.15	2209(E)	24.6.2016
292	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	1000ML Non-Glass	49.42	2209(E)	24.6.2016
293	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	100ML Glass	17.11	2209(E)	24.6.2016
294	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	100ML Non-Glass	15.46	2209(E)	24.6.2016
295	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	250ML Glass	23.67	2209(E)	24.6.2016
296	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	250ML Non-Glass	21.38	2209(E)	24.6.2016
297	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	500ML Glass	33.62	2209(E)	24.6.2016
298	Glucose (A) + Sodium Chloride (B)	Injection 5% (A) + 0.9% (B)	500ML Non-Glass	29.04	2209(E)	24.6.2016
299	Glucose	Injection 5%	1000ML Glass	60.78	2209(E)	24.6.2016
300	Glucose	Injection 5%	1000ML Non-Glass	49.04	2209(E)	24.6.2016
301	Glucose	Injection 5%	100ML Glass	17.06	2209(E)	24.6.2016
302	Glucose	Injection 5%	100ML Non-Glass	15.44	2209(E)	24.6.2016
303	Glucose	Injection 5%	250ML Glass	23.57	2209(E)	24.6.2016



304	Glucose	Injection 5%	250ML Non-Glass	21.29	2209(E)	24.6.2016
305	Glucose	Injection 5%	500ML Glass	33.45	2209(E)	24.6.2016
306	Glucose	Injection 5%	500ML Non-Glass	28.87	2209(E)	24.6.2016
307	Glyceryl Trinitratre	Sublingual Tablet 0.5 mg	1 Tablet	1.71	2569(E)	29.7.2016
308	Glycopyrrolate	Injection 0.2 mg/ML	1 ML	11.63	1404(E)	12.4.2016
309	Griseofulvin	Tablet 250 mg	1 Tablet	1.51	2195(E)	23.6.2016
310	Griseofulvin	Tablet 375 mg	1 Tablet	4.08	787(E)	10.03.2017
311	Haloperidol	Injection 5 mg/ML	1 ML	5.52	3181(E)	7.10.2016
312	Haloperidol	Oral liquid 2 mg/ 5ML	1 ML	1.95	1687(E)	9.5.2016
313	Haloperidol	Tablet 5 mg	1 Tablet	3.25	1404(E)	12.4.2016
314	Haloperidol	Tablet 1.5 mg	1 Tablet	1.56	1404(E)	12.4.2016
315	Haloperidol	Tablet 10 mg	1 Tablet	4.17	1404(E)	12.4.2016
316	Haloperidol	Tablet 20 mg	1 Tablet	4.66	1404(E)	12.4.2016
317	Halothane	Inhalation	1 ML	5.55	4128(E)	22.12.2016
318	Homatropine	Drops 2%	1 ML	5.64	3431(E)	10.11.2016
319	Human chorionic Gonadotropin	Injection 1000 IU	Each Pack	192.84	1560(E)	27.4.2016
320	Human chorionic Gonadotropin	Injection 5000 IU	Each Pack	378.71	1560(E)	27.4.2016
321	Human Normal Immunoglobulin		1 ML	139.98	787(E)	10.03.2017
322	Hydrochlorothiazide	Tablet 50 mg	1 Tablet	0.07830	442(E)	14.2.2017
323	Hydrochlorothiazide	Tablet 12.5 mg	1 Tablet	0.93	2963(E)	15.09.2016
324	Hydrochlorothiazide	Tablet 25 mg	1 Tablet	1.60	2963(E)	15.09.2016
325	Hydrocortisone	Injection 200 mg	Each Pack	54.44	3431(E)	10.11.2016
326	Hydrocortisone	Injection 100mg	Each Pack	35.31	1686(E)	9.5.2016
327	Hydrocortisone	Powder for Injection 100mg	Each Pack	35.31	1687(E)	9.5.2016
328	Hydroxychloroquine	Tablet 200 mg	1 Tablet	5.61	1819(E)	18.5.2016
329	Hydroxychloroquine	Tablet 400 mg	1 Tablet	11.30	1254(E)	29.3.2016
330	Hydroxypropyl methylcellulose	Injection 2%	1 ML	35.48	1560(E)	27.4.2016
331	Hydroxyurea	Capsule 500 mg	1 Capsule	11.63	1254(E)	29.3.2016
332	Hyoscine Butylbromide	Tablet 10mg	1 Tablet	2.82	1951(E)	2.6.2016
333	Hyoscine butylbromide	Injection 20 mg/ML	1 ML	9.86	4128(E)	22.12.2016
334	Ibuprofen	Tablet 200mg	1 Tablet	0.36	2730(E)	17.8.2016
335	Ibuprofen	Tablet 400mg	1 Tablet	0.66	2730(E)	17.8.2016
336	Ibuprofen	Oral liquid 100mg/5ML	1 ML	0.18	4128(E)	22.12.2016
337	Imatinib	Capsule 400 mg	1 Capsule	241.66	3430(E)	10.11.2016
338	Imatinib	Tablet 400mg	1 Tablet	217.53	1951(E)	2.6.2016
339	Imatinib	Capsule 100mg	1 Capsule	73.45	3180(E)	7.10.2016
340	Insulin (Soluble)	Injection 40 IU/ML	1 ML	13.66	2193(E)	23.6.2016
341	Intermediate Acting (NPH) Insulin	injection 40 IU/ML	1 ML	13.66	2193(E)	23.6.2016
342	Ipratropium	Inhalation (MDI/DPI) 20 mcg/dose	1 Dose	0.58	4128(E)	22.12.2016
343	Ipratropium	Respirator solution for use in nebulizer 250 mcg/ML	1 ML	2.40	1560(E)	27.4.2016
344	Iron sucrose	Injection 20 mg/ML	1 ML	50.85	1404(E)	12.4.2016
345	Isoflurane	Inhalation	1 ML	9.48	443(E)	14.2.2017
346	Isosorbide dinitrate	Tablet 10 mg	1 Tablet	0.70	1254(E)	29.3.2016
347	Isosorbide dinitrate	Tablet 5 mg	1 Tablet	0.72	1254(E)	29.3.2016
348	Isosorbide-5-mononitrate	SR Tablet 30 mg	1 Tablet	4.63	1254(E)	29.3.2016
349	Isosorbide-5-mononitrate	SR Tablet 60 mg	1 Tablet	6.04	1254(E)	29.3.2016
350	Isosorbide-5-mononitrate	Tablet 10 mg	1 Tablet	1.86	443(E)	14.2.2017
351	Isosorbide-5-mononitrate	Tablet 20 mg	1 Tablet	2.90	443(E)	14.2.2017



352	Ispaghula	Granules/ Husk/ Powder	1 GM	0.74	443(E)	14.2.2017
353	Kanamycin	Powder for injection 500 mg	Each Pack	20.19	2962(E)	15.09.2016
354	Kanamycin	Powder for Injection 1 GM	Each Pack	36.99	1404(E)	12.4.2016
355	Kanamycin	Powder for Injection 750 mg	Each Pack	34.48	1404(E)	12.4.2016
356	Ketamine	Injection 50 mg/ML	1 ML	9.88	3181(E)	7.10.2016
357	Ketamine	Injection 10 mg/ML	1 ML	10.02	3181(E)	7.10.2016
358	Labetalol	Injection 5 mg/ML	1 ML	47.96	1560(E)	27.4.2016
359	Lactulose	Oral liquid 10 g/15 ML	1 ML	1.00	1560(E)	27.4.2016
360	Lamivudine (A) + Nevirapine (B) + Stavudine (C)	Tablet 150 mg (A) + 200 mg (B) + 30 mg(C)	1 Tablet	14.76	4128(E)	22.12.2016
361	Lamivudine (A) + Zidovudine (B)	Tablet 150mg (A) + 300mg (B)	1 Tablet	18.98	2569(E)	29.7.2016
362	L-Asparaginase	Powder for Injection 10000 KU	Each Pack	1,518.86	1404(E)	12.4.2016
363	Leflunomide	Tablet 20 mg	1 Tablet	18.49	2195(E)	23.6.2016
364	Leflunomide	Tablet 10 mg	1 Tablet	9.48	2195(E)	23.6.2016
365	Letrozole	Tablet 2.5 mg	1 Tablet	37.00	1404(E)	12.4.2016
366	Levetiracetam	ER Tablet 750 mg	1 Tablet	16.45	1254(E)	29.3.2016
367	Levetiracetam	Injection 100mg/ML	1 ML	20.65	1687(E)	9.5.2016
368	Levetiracetam	Tablet 250 mg	1 Tablet	5.54	1254(E)	29.3.2016
369	Levetiracetam	Tablet 500 mg	1 Tablet	11.19	1254(E)	29.3.2016
370	Levetiracetam	Tablet 750 mg	1 Tablet	17.19	1254(E)	29.3.2016
371	Levetiracetam	Oral Liquid 100mg/ML	1 ML	3.45	2964(E)	15.9.2016
372	Levodopa (A) + Carbidopa (B)	Tablet 100mg (A) + 10mg (B)	1 Tablet	1.47	1819(E)	18.5.2016
373	Levodopa (A) + Carbidopa (B)	Tablet 250mg (A) + 25 mg (B)	1 Tablet	3.53	2963(E)	15.09.2016
374	Levodopa (A) + Carbidopa (B)	CR Tablet 100 mg (A) + 25 mg (B)	1 Tablet	3.16	1254(E)	29.3.2016
375	Levodopa (A) + Carbidopa (B)	Tablet 100mg (A) + 25mg (B)	1 Tablet	2.14	1819(E)	18.5.2016
376	Levofloxacin	Tablet 750 mg	1 Tablet	10.34	1254(E)	29.3.2016
377	Levofloxacin	Tablet 250 mg	1 Tablet	4.17	1254(E)	29.3.2016
378	Levofloxacin	Tablet 500 mg	1 Tablet	6.35	1254(E)	29.3.2016
379	Levothyroxine	Tablet 100 mcg	1 Tablet	1.13	1254(E)	29.3.2016
380	Levothyroxine	Tablet 12.5 mcg	1 Tablet	1.28	1254(E)	29.3.2016
381	Levothyroxine	Tablet 125 mcg	1 Tablet	1.45	1254(E)	29.3.2016
382	Levothyroxine	Tablet 150mcg	1 Tablet	1.46	1254(E)	29.3.2016
383	Levothyroxine	Tablet 25 mcg	1 Tablet	1.24	1254(E)	29.3.2016
384	Levothyroxine	Tablet 50 mcg	1 Tablet	0.93	1254(E)	29.3.2016
385	Levothyroxine	Tablet 75 mcg	1 Tablet	1.23	1254(E)	29.3.2016
386	Levothyroxine	Tablet 88 mcg	1 Tablet	1.45	1254(E)	29.3.2016
387	Lignocaine	Injection 2%	1 ML	0.93	3181(E)	7.10.2016
388	Lignocaine	Injection 2%(Preservative free for IV use)	1 ML	0.92	443(E)	14.2.2017
389	Lignocaine	Injection 1%	Each Pack	7.51	3181(E)	7.10.2016
390	Lignocaine	Topical forms Injection 2-5%	1 GM or 1 ML	0.99	788(E)	10.03.2017
391	Lignocaine (A) + Adrenaline (B)	Injection 2% (A) +	1 ML	0.87	443(E)	14.2.2017

		1:200000 (5mcg/ML) (B)				
392	Linezolid	Tablet 600 mg	1 Tablet	31.26	1254(E)	29.3.2016
393	Lithium	Tablet 300 mg	1 Tablet	1.38	3181(E)	7.10.2016
394	Loperamide	Capsule 2mg	1 Capsule	3.39	1687(E)	9.5.2016
395	Loperamide	Tablet 2 mg	1 Tablet	1.87	1404(E)	12.4.2016
396	Lopinavir (A) + Ritonavir (B)	Tablet 200 mg (A) + 50 mg (B)	1 Tablet	43.12	1254(E)	29.3.2016
397	Lorazepam	injection 2 mg/ML	1 ML	7.36	3431(E)	10.11.2016
398	Lorazepam	Tablet 1 mg	1 Tablet	1.96	1254(E)	29.3.2016
399	Lorazepam	Tablet 2 mg	1 Tablet	2.38	1254(E)	29.3.2016
400	Mannitol	Injection 20%	1 ML	0.28	3431(E)	10.11.2016
401	Mebendazole	Oral liquid 100 mg/5 ML	1 ML	0.74	1560(E)	27.4.2016
402	Mebendazole	Tablet 100 mg	1 Tablet	2.77	1254(E)	29.3.2016
403	Medroxyprogesteroneacetate	Tablet 10 mg	1 Tablet	5.09	2195(E)	23.6.2016
404	Mefenamic acid	Oral liquid 100 mg/5 ML	1 ML	0.49	1560(E)	27.4.2016
405	Mefenamic acid	Tablet 500 mg	1 Tablet	2.31	4127(E)	22.12.2016
406	Mefenamic acid	Tablet 250 mg	1 Tablet	1.82	4127(E)	22.12.2016
407	Mefloquine	Tablet 250 mg	1 Tablet	48.24	2195(E)	23.6.2016
408	Melphalan	Tablet 2mg	1 Tablet	89.02	2569(E)	29.7.2016
409	Melphalan	Tablet 5mg	1 Tablet	152.68	2569(E)	29.7.2016
410	Mesna	Injection 100 mg/ML	1 ML	15.22	1560(E)	27.4.2016
411	Metformin	Immediate Release Tablet 1000 mg	1 Tablet	3.41	1254(E)	29.3.2016
412	Metformin	Controlled Release Tablet 750 mg	1 Tablet	2.27	4127(E)	22.12.2016
413	Metformin	Immediate Release Tablet 750 mg	1 Tablet	2.88	4127(E)	22.12.2016
414	Metformin	Controlled ReleaseTablet 1000 mg	1 Tablet	3.45	1254(E)	29.3.2016
415	Metformin	Controlled ReleaseTablet 500 mg	1 Tablet	1.80	1254(E)	29.3.2016
416	Metformin	Tablet (Immediate Release)500mg	1 Tablet	1.42	1951(E)	2.6.2016
417	Methotrexate	Injection 25 mg/ ML	1 ML	43.64	1404(E)	12.4.2016
418	Methotrexate	Injection 50 mg/ML	1 ML	36.35	4128(E)	22.12.2016
419	Methotrexate	Tablet 2.5 mg	1 Tablet	4.34	2195(E)	23.6.2016
420	Methotrexate	Tablet 10 mg	1 Tablet	11.02	2195(E)	23.6.2016
421	Methotrexate	Tablet 7.5 mg	1 Tablet	10.52	2195(E)	23.6.2016
422	Methotrexate	Tablet 5 mg	1 Tablet	7.60	2963(E)	15.09.2016
423	Methylidopa	Tablet 250 mg	1 Tablet	2.30	788(E)	10.03.2017
424	Methylidopa	Tablet 500 mg	1 Tablet	4.42	787(E)	10.03.2017
425	Methylergometrine	Injection 0.2 mg/ML	1 ML	13.50	4128(E)	22.12.2016
426	Methylergometrine	Tablet 0.125 mg	1 Tablet	7.49	248(E)	24.01.2017
427	Methylprednisolone	Injection 40 mg/ML	1 ML	45.41	248(E)	24.01.2017
428	Methylprednisolone	Tablet 16 mg	1 Tablet	8.44	1254(E)	29.3.2016
429	Methylprednisolone	Tablet 8 mg	1 Tablet	4.83	1254(E)	29.3.2016
430	Metoclopramide	Oral Liquid 5 mg/5ML	1 ML	0.42	3431(E)	10.11.2016
431	Metoclopramide	Tablet 10mg	1 Tablet	1.10	2569(E)	29.7.2016
432	Metoprolol	Capsule 25mg	1 Capsule	4.00	1687(E)	9.5.2016



433	Metoprolol	Tablet 25mg	1 Tablet	2.94	1951(E)	2.6.2016
434	Metoprolol	Capsule 50mg	1 Capsule	6.10	1687(E)	9.5.2016
435	Metoprolol	SR Tablet 25 mg	1 Tablet	3.82	1254(E)	29.3.2016
436	Metoprolol	SR Tablet 50 mg	1 Tablet	5.46	1254(E)	29.3.2016
437	Metoprolol	Tablet 50mg	1 Tablet	4.45	1951(E)	2.6.2016
438	Metronidazole	Injection 500 mg/100 ML	1 ML	0.12276	443(E)	14.2.2017
439	Metronidazole	Oral liquid 200 mg/5 ML	1 ML	0.28	3182(E)	7.10.2016
440	Metronidazole	Tablet 400 mg	1 Tablet	0.76	1819(E)	18.5.2016
441	Metronidazole	Tablet 200 mg	1 Tablet	0.41	2195(E)	23.6.2016
442	Midazolam	Injection 5mg/ML	1 ML	13.73	4128(E)	22.12.2016
443	Midazolam	Injection 1mg/ML	1 ML	5.59	4128(E)	22.12.2016
444	Mifepristone	Tablet 200mg	1 Tablet	304.38	1819(E)	18.5.2016
445	Misoprostol	Tablet 100 mcg	1 Tablet	8.24	2730(E)	17.8.2016
446	Misoprostol	Tablet 200 mcg	1 Tablet	15.80	1254(E)	29.3.2016
447	Moxifloxacin	Tablet 400 mg	1 Tablet	23.97	1254(E)	29.3.2016
448	Mycophenolate mofetil	Tablet 250 mg	1 Tablet	37.67	1404(E)	12.4.2016
449	Mycophenolate mofetil	Tablet 500 mg	1 Tablet	74.53	1404(E)	12.4.2016
450	N-acetylcysteine	Injection 200 mg/ML	1 ML	21.20	4128(E)	22.12.2016
451	N-acetylcysteine	Sachet 200 mg	1 GM	7.13	4127(E)	22.12.2016
452	Naloxone	injection 0.4 mg/ML	1 ML	82.08	3431(E)	10.11.2016
453	Natamycin	Drops 5%	1 ML	21.58	1560(E)	27.4.2016
454	Neostigmine	injection 0.5 mg/ML	1 ML	4.12	2730(E)	17.8.2016
455	Neostigmine	Tablet 15 mg	1 Tablet	4.41	4128(E)	22.12.2016
456	Nevirapine	Oral Liquid 50mg/5ML	1 ML	0.79	4128(E)	22.12.2016
457	Nevirapine	Tablet 200 mg	1 Tablet	13.54	1254(E)	29.3.2016
458	Nifedipine	Capsule 10 mg	1 Capsule	0.81	4128(E)	22.12.2016
459	Nifedipine	Tablet 10 mg	1 Tablet	1.17	2195(E)	23.6.2016
460	Nitrofurantoin	Capsule 100 mg	1 Capsule	6.64	3180(E)	7.10.2016
461	Nitrofurantoin	Oral liquid 25 mg/5 ML	1 ML	0.77	1560(E)	27.4.2016
462	Nitrofurantoin	Tablet 100 mg	1 Tablet	6.84	2730(E)	17.8.2016
463	Norethisterone	Tablet 5mg	1 Tablet	4.84	1951(E)	2.6.2016
464	Omeprazole	Capsule 10mg	1 Capsule	2.00	248(E)	24.01.2017
465	Omeprazole	Tablet 10mg	1 Tablet	4.19	247(E)	24.01.2017
466	Omeprazole	Tablet 40 mg	1 Tablet	7.89	3180(E)	7.10.2016
467	Omeprazole	Capsule 20mg	1 Capsule	2.36	1819(E)	18.5.2016
468	Omeprazole	Capsule 40mg	1 Capsule	4.67	4128(E)	22.12.2016
469	Omeprazole	Powder for oral liquid 20mg	1 GM	1.16	247(E)	24.01.2017
470	Omeprazole	Tablet 20 mg	1 Tablet	4.66	4127(E)	22.12.2016
471	Ondansetron	Injection 2mg/ML	1 ML	5.54	1951(E)	2.6.2016
472	Ondansetron	Tablet 4mg	1 Tablet	4.44	1951(E)	2.6.2016
473	Ondansetron	Oral liquid 2 mg/5ML	1 ML	1.06	3181(E)	7.10.2016
474	Ondansetron	Tablet 8 mg	1 Tablet	9.24	2195(E)	23.6.2016
475	Oral Rehydration Salts	As Licensed	1 GM	0.72	1819(E)	18.5.2016
476	Oral Rehydration Salts	As Licensed	1 ML	0.12897	1818(E)	18.5.2016
477	Oxytocin	Injection 5IU/ML	1 ML	16.69	4128(E)	22.12.2016
478	Paclitaxel	Injection 30mg / 5ML	1 ML	211.16	1561 (E)	27.4.2016
479	Paclitaxel	Injection 100 mg/16.7 ML	1 ML	211.16	1560(E)	27.4.2016



480	Pantoprazole	Injection 40mg	Each Pack	42.13	1951(E)	2.6.2016
481	Paracetamol	injection 150mg/ML	Each Pack (2ML)	6.10	248(E)	24.01.2017
482	Paracetamol	Oral Liquid 250mg/5ML	1 ML	0.57	2962(E)	15.09.2016
483	Paracetamol	Oral Liquid 120 mg/5ML	1 ML	0.50	3430(E)	10.11.2016
484	Paracetamol	Oral Liquid 125 mg/5ML	1 ML	0.32	3431(E)	10.11.2016
485	Paracetamol	Suppository 80mg	Each Suppository	6.16	3431(E)	10.11.2016
486	Paracetamol	Suppository 170mg	Each Suppository	7.28	3431(E)	10.11.2016
487	Paracetamol	Tablet 500mg	1 Tablet	0.85	1951(E)	2.6.2016
488	Paracetamol	Tablet 650 mg	1 Tablet	1.74	1254(E)	29.3.2016
489	Paracetamol	Oral Liquid 150 mg/5ML	1 ML	0.55	2962(E)	15.09.2016
490	Paracetamol	Oral Liquid 100 mg/5ML	1 ML	0.48	2962(E)	15.09.2016
491	Paracetamol	Oral Liquid 650 mg/5ML	1 ML	0.49	2962(E)	15.09.2016
492	Paracetamol	Oral Liquid 500 mg/5ML	1 ML	0.60	2962(E)	15.09.2016
493	Pegylated interferon alfa 2b	Injection 100mcg	Each Pack	14,802.08	1687(E)	9.5.2016
494	Pegylated interferon alfa 2b	Injection 80mcg	Each Pack	11,833.84	1687(E)	9.5.2016
495	Penicillamine	Capsule 250mg	1 Capsule	13.49	1686(E)	9.5.2016
496	Permethrin	Cream 5%	1 GM	1.65	3181(E)	7.10.2016
497	Permethrin	Lotion 1%	1 GM	0.86	248(E)	24.01.2017
498	Pheniramine	Injection 22.75 mg/ML	1 ML	1.05	3431(E)	10.11.2016
499	Phenobarbitone	Oral Liquid 20mg/5ML	1 ML	0.36	443(E)	14.2.2017
500	Phenobarbitone	Injection 200mg/ML	1 ML	18.13	2730(E)	17.8.2016
501	Phenobarbitone	Tablet 60mg	1 Tablet	1.67	1951(E)	2.6.2016
502	Phenobarbitone	Tablet 30 mg	1 Tablet	1.14	2195(E)	23.6.2016
503	Phenytoin	Capsule 300mg	1 Capsule	3.61	247(E)	24.01.2017
504	Phenytoin	Capsule 100 mg	1 Capsule	1.44	248(E)	24.01.2017
505	Phenytoin	ER Capsule 300mg	1 Capsule	3.61	247(E)	24.01.2017
506	Phenytoin	ER Tablet 300mg	1 Tablet	5.50	1254(E)	29.3.2016
507	Phenytoin	injection 25 mg/ML	1 ML	2.38	3431(E)	10.11.2016
508	Phenytoin	Oral liquid 125 mg/5 ML	1 ML	0.84	247(E)	24.01.2017
509	Phenytoin	Oral liquid 30 mg/5 ML	1 ML	0.28	442(E)	14.2.2017
510	Phenytoin	Tablet 50mg	1 Tablet	0.71	1686(E)	9.5.2016
511	Phenytoin	Tablet 300mg	1 Tablet	4.48	1254(E)	29.3.2016
512	Phenytoin	Injection 50 mg/ML	1 ML	5.08	3181(E)	7.10.2016
513	Pilocarpine	Drops 2%	1 ML	9.56	3431(E)	10.11.2016
514	Piperacillin (A) + Tazobactam (B)	Powder for Injection 1 g (A) + 125 mg (B)	Each Pack	83.64	1404(E)	12.4.2016
515	Piperacillin (A) + Tazobactam (B)	Powder for Injection 2 g (A) + 250 mg (B)	Each Pack	197.86	1404(E)	12.4.2016
516	Piperacillin (A) + Tazobactam (B)	Powder for Injection 4 g (A) + 500 mg (B)	Each Pack	415.63	1404(E)	12.4.2016
517	Potassium chloride	Injection 150 mg/ML	1 ML	2.29	1560(E)	27.4.2016



518	Potassium chloride	Oral liquid 500 mg/5 ML	1 ML	0.27	1687(E)	9.5.2016
519	Povidone iodine	Solution 7.5%	1 ML	0.74	1687(E)	9.5.2016
520	Povidone iodine	Solution 4%	1 ML	1.65	247(E)	24.01.2017
521	Povidone iodine	Solution 5%	1 ML	0.34	3431(E)	10.11.2016
522	Povidone iodine	Solution 10%	1 ML	0.67	443(E)	14.2.2017
523	Pralidoxime chloride (2-PAM)	Injection 25 mg/ML	1 ML	3.52	3430(E)	10.11.2016
524	Prednisolone	Drops 1%	1 ML	3.18	1561 (E)	27.4.2016
525	Prednisolone	Oral liquid 5mg / 5ML	1 ML	0.41	1560(E)	27.4.2016
526	Prednisolone	Tablet 5 mg	1 Tablet	0.53	1819(E)	18.5.2016
527	Prednisolone	Tablet 10 mg	1 Tablet	0.92	1819(E)	18.5.2016
528	Prednisolone	Tablet 20 mg	1 Tablet	1.85	2195(E)	23.6.2016
529	Prednisolone	Oral liquid 15mg / 5ML	1 ML	0.72	1560(E)	27.4.2016
530	Premix Insulin 30:70 Injection (Regular:NPH)	Injection 40 IU /ML	1 ML	13.66	2193(E)	23.6.2016
531	Prilocaine (A) + Lignocaine (B)	Cream 2.5% (A) + 2.5% (B)	1 GM	19.34	1687(E)	9.5.2016
532	Primaquine	Tablet 7.5 mg	1 Tablet	2.00	2730(E)	17.8.2016
533	Primaquine	Tablet 15 mg	1 Tablet	4.34	2729(E)	17.8.2016
534	Primaquine	Tablet 2.5 mg	1 Tablet	1.47	2963(E)	15.09.2016
535	Procarbazine	Tablet 50 mg	1 Tablet	42.74	247(E)	24.01.2017
536	Procarbazine	Capsule 50 mg	1 Capsule	31.37	2730(E)	17.8.2016
537	Proparacaine	Drops 0.5%	1 ML	9.44	1560(E)	27.4.2016
538	Propofol	Injection 10 mg/ML	1 ML	6.83	3181(E)	7.10.2016
539	Propranolol	Capsule 80mg	1 Capsule	5.46	1687(E)	9.5.2016
540	Propranolol	Capsule 40 mg	1 Capsule	3.60	3180(E)	7.10.2016
541	Propranolol	Tablet 40mg	1 Tablet	2.61	444(E)	14.2.2017
542	Propranolol	Tablet 80 mg	1 Tablet	4.72	1254(E)	29.3.2016
543	Propranolol	Tablet 10 mg	1 Tablet	1.09	2195(E)	23.6.2016
544	Protamine	Injection 10mg/ML	1 ML	8.39	3181(E)	7.10.2016
545	Pyrazinamide	Tablet 500 mg	1 Tablet	3.84	2195(E)	23.6.2016
546	Pyrazinamide	Tablet 750 mg	1 Tablet	5.84	2195(E)	23.6.2016
547	Pyrazinamide	Tablet 1000 mg	1 Tablet	8.56	2195(E)	23.6.2016
548	Pyrazinamide	Tablet 1500mg	1 Tablet	9.47	2569(E)	29.7.2016
549	Pyridoxine	Tablet 100 mg	1 Tablet	5.30	1254(E)	29.3.2016
550	Quinine	Injection 300 mg/ML	1 ML	9.22	4128(E)	22.12.2016
551	Quinine	Tablet 300 mg	1 Tablet	5.19	2195(E)	23.6.2016
552	Rabies Vaccine		Each Pack	310.08	1686(E)	9.5.2016
553	Raltegravir	Tablet 400 mg	1 Tablet	142.00	1254(E)	29.3.2016
554	Ramipril	Capsule 2.5mg	1 Capsule	4.47	1687(E)	9.5.2016
555	Ramipril	Capsule 5mg	1 Capsule	6.99	1687(E)	9.5.2016
556	Ramipril	Tablet 2.5 mg	1 Tablet	4.70	1254(E)	29.3.2016
557	Ramipril	Tablet 5 mg	1 Tablet	7.42	1254(E)	29.3.2016
558	Ranitidine	Injection 25 mg/ML	1 ML	1.51	3431(E)	10.11.2016
559	Ranitidine	Oral liquid 75 mg/5 ML	1 ML	0.55	1560(E)	27.4.2016
560	Ranitidine	Tablet 150 mg	1 Tablet	0.70	1254(E)	29.3.2016
561	Ribavirin	Capsule 200 mg	1 Capsule	75.90	1254(E)	29.3.2016
562	Rifampicin	Capsule 600 mg	1 Capsule	10.98	1254(E)	29.3.2016
563	Rifampicin	Tablet 300 mg	1 Tablet	2.77	3431(E)	10.11.2016
564	Risperidone	Oral liquid 1 mg/ML	1 ML	1.82	1560(E)	27.4.2016



565	Risperidone	Tablet 2 mg	1 Tablet	4.66	1404(E)	12.4.2016
566	Risperidone	Tablet 4 mg	1 Tablet	9.47	1404(E)	12.4.2016
567	Risperidone	Tablet 1 mg	1 Tablet	2.91	1404(E)	12.4.2016
568	Ritonavir	Tablet 100 mg	1 Tablet	27.45	2729(E)	17.8.2016
569	Ritonavir	Capsule 100 mg	1 Capsule	26.70	3431(E)	10.11.2016
570	Rituximab	Injection 10 mg/ML	1 ML	717.63	1404(E)	12.4.2016
571	Salbutamol	Tablet 2 mg	1 Tablet	0.15131	2730(E)	17.8.2016
572	Salbutamol	Capsule 4 mg	1 Capsule	0.57	3430(E)	10.11.2016
573	Salbutamol	Inhalation (MDI/DPI) 100 mcg/dose	1 Dose	0.38	443(E)	14.2.2017
574	Salbutamol	Oral liquid 2 mg/5 ML	1 ML	0.15	4128(E)	22.12.2016
575	Salbutamol	Respirator solution for use in nebulizer 5mg/ML	1 ML	0.67	1687(E)	9.5.2016
576	Salbutamol	Tablet 4 mg	1 Tablet	0.17335	2195(E)	23.6.2016
577	Salicylic acid	Ointment 6%	1 GM	1.70	1560(E)	27.4.2016
578	Sodium Bicarbonate	Injection 8.4%	1 ML	1.22	443(E)	14.2.2017
579	Sodium Bicarbonate	Injection 7.5%	1 ML	1.32	443(E)	14.2.2017
580	Sodium Chloride	Injection 0.9%	1000ML Glass	56.15	2209(E)	24.6.2016
581	Sodium Chloride	Injection 0.9%	1000ML Non-Glass	44.29	2209(E)	24.6.2016
582	Sodium Chloride	Injection 0.9%	100ML Glass	16.61	2209(E)	24.6.2016
583	Sodium Chloride	Injection 0.9%	100ML Non-Glass	14.96	2209(E)	24.6.2016
584	Sodium Chloride	Injection 0.9%	250ML Glass	22.39	2209(E)	24.6.2016
585	Sodium Chloride	Injection 0.9%	250ML Non-Glass	20.11	2209(E)	24.6.2016
586	Sodium Chloride	Injection 0.9%	500ML Glass	31.12	2209(E)	24.6.2016
587	Sodium Chloride	Injection 0.9%	500ML Non-Glass	26.51	2209(E)	24.6.2016
588	Sodium Nitroprusside	Injection 10 mg/ML	1 ML	24.42	1819(E)	18.5.2016
589	Sodium valproate	Tablet 300 mg	1 Tablet	3.76	1254(E)	29.3.2016
590	Sodium valproate	Tablet 200 mg	1 Tablet	2.80	2195(E)	23.6.2016
591	Sodium valproate	Tablet 500 mg	1 Tablet	6.56	2195(E)	23.6.2016
592	Sodium Valproate	Injection 100 mg/ML	1 ML	5.45	2963(E)	15.09.2016
593	Sodium Valproate	Oral Liquid 200mg/5ML	1 ML	0.55	4128(E)	22.12.2016
594	Sofosbuvir	Tablet 400 mg	1 Tablet	631.52	1254(E)	29.3.2016
595	Somatostatin	Powder for Injection 3 mg	Each pack	1,438.04	1404(E)	12.4.2016
596	Spironolactone	Tablet 25 mg	1 Tablet	1.80	788(E)	10.03.2017
597	Stavudine (A) + Lamivudine (B)	Tablet 30mg (A) +150mg (B)	1 Tablet	9.03	2569(E)	29.7.2016
598	Streptokinase	Injection 7,50,000 IU	Each Pack	1,191.15	3431(E)	10.11.2016
599	Streptokinase	Injection 15,00,000 IU	Each Pack	1,693.59	3431(E)	10.11.2016
600	Streptomycin	Powder for Injection 750 mg	Each Pack	7.97	3181(E)	7.10.2016
601	Streptomycin	Powder for Injection 1GM	Each Pack	9.46	248(E)	24.01.2017
602	Sucralfate	Oral liquid 1 GM	1 ML	0.67	1560(E)	27.4.2016
603	Sulfasalazine	Tablet 500 mg	1 Tablet	3.77	1819(E)	18.5.2016
604	Tacrolimus	Capsule 2 mg	1 Capsule	72.40	1404(E)	12.4.2016
605	Tamoxifen	Tablet 10 mg	1 Tablet	2.44	2730(E)	17.8.2016
606	Tamoxifen		1 Tablet	2.75	2730(E)	17.8.2016
607	Telmisartan	Tablet 80 mg	1 Tablet	9.51	1254(E)	29.3.2016

608	Telmisartan	Tablet 20 mg	1 Tablet	3.45	1254(E)	29.3.2016
609	Telmisartan	Tablet 40 mg	1 Tablet	6.24	1254(E)	29.3.2016
610	Temozolomide	Capsule 250 mg	1 Capsule	4,434.02	1404(E)	12.4.2016
611	Temozolomide	Capsule 100 mg	1 Capsule	1,971.40	1404(E)	12.4.2016
612	Temozolomide	Capsule 20 mg	1 Capsule	564.30	1404(E)	12.4.2016
613	Temozolomide	Tablet 20mg	1 Tablet	354.54	1687(E)	9.5.2016
614	Temozolomide	Tablet 100mg	1 Tablet	1,463.33	1687(E)	9.5.2016
615	Temozolomide	Tablet 250mg	1 Tablet	3,621.90	1687(E)	9.5.2016
616	Tenofovir	Tablet 300 mg	1 Tablet	44.65	1254(E)	29.3.2016
617	Tenofovir (A) + Lamivudine (B)	Tablet 300 mg (A) +300 mg (B)	1 Tablet	40.73	1254(E)	29.3.2016
618	Tenofovir (A) + Lamivudine (B) + Efavirenz (C)	Tablet 300 mg (A) + 300 mg (B) + 600 mg (C)	1 Tablet	93.52	1254(E)	29.3.2016
619	Tetanus Toxoid	Injection	Each Pack (0.5ML)	5.64	248(E)	24.01.2017
620	Tetanus Toxoid	Injection	Each Pack (5ML)	24.89	248(E)	24.01.2017
621	Thalidomide	Capsule 50 mg	1 Capsule	33.40	1404(E)	12.4.2016
622	Thalidomide	Capsule 100 mg	1 Capsule	57.80	1404(E)	12.4.2016
623	Thiamine	Injection 100 mg/ML	1 ML	23.47	1560(E)	27.4.2016
624	Thiamine	Tablet 100 mg	1 Tablet	3.54	4128(E)	22.12.2016
625	Thiopentone	Powder for Injection 1 GM	Each Pack	46.76	3181(E)	7.10.2016
626	Thiopentone	Powder for Injection 0.5 GM	Each Pack	38.54	4128(E)	22.12.2016
627	Timolol	Drops 0.5%	1 ML	11.28	4128(E)	22.12.2016
628	Timolol	Drops 0.25%	1 ML	4.88	3431(E)	10.11.2016
629	Tiotropium	Inhalation (DPI) 18 mcg/dose	1 Dose	2.34	1687(E)	9.5.2016
630	Tiotropium	Inhalation (MDI) 9 mcg/dose	1 Dose	2.20	1687(E)	9.5.2016
631	Tramadol	Tablet 50mg	1 Tablet	7.63	4127(E)	22.12.2016
632	Tramadol	Capsule 50 mg	1 Capsule	4.28	2195(E)	23.6.2016
633	Tramadol	Tablet 100mg	1 Tablet	18.61	1687(E)	9.5.2016
634	Tranexamic acid	Injection 100 mg/ML	1 ML	13.55	1404(E)	12.4.2016
635	Tranexamic acid	Tablet 500 mg	1 Tablet	15.76	1254(E)	29.3.2016
636	Trastuzumab	Injection 440 mg/50 ML	Each Pack	56,912.83	1687(E)	9.5.2016
637	Trihexyphenidyl	Tablet 2mg	1 Tablet	1.15	1951(E)	2.6.2016
638	Tropicamide	Eye Drop 1%	1 ML	9.52	3431(E)	10.11.2016
639	Vancomycin	Powder for Injection 1 GM	Each Pack	431.83	4128(E)	22.12.2016
640	Vancomycin	Powder for Injection 500 mg	Each Pack	259.74	4128(E)	22.12.2016
641	Vecuronium	Powder for Injection 10 mg	Each Pack	171.56	1560(E)	27.4.2016
642	Vecuronium	Powder for Injection 4 mg	Each Pack	82.80	1560(E)	27.4.2016
643	Verapamil	Injection 2.5 mg/ML	1 ML	1.10	788(E)	10.03.2017
644	Verapamil	Tablet 40 mg	1 Tablet	0.71	788(E)	10.03.2017
645	Verapamil	Tablet 80 mg	1 Tablet	1.31	788(E)	10.03.2017
646	Vincristine	Injection 1 mg/ML	1 ML	47.28	3181(E)	7.10.2016
647	Vitamin A	Injection 50000 IU/ML	1 ML	1.80	788(E)	10.03.2017
648	Vitamin A	Tablet 50000 IU	1 Tablet	0.67	787(E)	10.03.2017

649	Warfarin	Tablet 5 mg	1 Tablet	2.24	2195(E)	23.6.2016
650	Warfarin	Tablet 1mg	1 Tablet	2.28	1254(E)	29.3.2016
651	Water for Injection	Injection	Each Pack (10 ML)	2.21	443(E)	14.2.2017
652	Water for Injection	Injection	Each Pack (5 ML)	2.13	443(E)	14.2.2017
653	Xylometazoline	Nasal Drops 0.1%	1 ML	4.92	1560(E)	27.4.2016
654	Xylometazoline	Nasal Drops 0.05%	1 ML	3.72	1560(E)	27.4.2016
655	Zidovudine	Tablet 300 mg	1 Tablet	12.94	2569(E)	29.7.2016
656	Zidovudine	Capsule 300 mg	1 Capsule	1.88	247(E)	24.01.2017
657	Zidovudine (A) + Lamivudine (B) + Nevirapine (C)	Tablet 300 mg (A) + 150 mg (B) + 200 mg(C)	1 Tablet	19.06	248(E)	24.01.2017
658	Zolpidem	Capsule 5mg	1 Capsule	6.96	442(E)	14.2.2017
659	Zolpidem	Tablet 10 mg	1 Tablet	7.99	1404(E)	12.4.2016
660	Zolpidem	Tablet 5 mg	1 Tablet	5.09	1404(E)	12.4.2016

Notes:-

- (a) The ceiling prices are applicable with effect from 01.4.2017 (ceiling prices are inclusive of Wholesale Price Index (WPI) @ 1.97186% for the year 2016 over 2015).
- (b) In respect of Gentamycin injection 40mg/ml, Dexamethasone injection 4mg/ml, Paracetamol injection 150mg/ml, Glucose Injection 5%, Sodium chloride Injection 0.9%, Glucose + Sodium chloride Injection 5%+0.9%, Water for Injection and Tetanus Toxoid injection, for any other pack size manufactured, the manufacturer shall approach NPPA for specific price approval for its formulations.
- (c) In respect of any other scheduled formulation, for which ceiling price is not mentioned above or in S.O. 1008, 1009, 1010 dated 30.3.2017 or in S.O 412(E) dated 13.2.2017, the manufacturer shall approach the NPPA for specific price approval for its formulations.
- (d) All manufacturers of scheduled formulations, selling branded or generic or both the versions of scheduled formulations at price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- (e) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table (plus local taxes as applicable, if any), may revise the existing M.R.P. of their formulations, on the basis of WPI @ 1.97186% for year 2016 in accordance with paragraph 16(2) of DPCO, 2013, read with para 13(2) of DPCO, 2013.
- (f) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (g) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (h) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (i) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.



- (j) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (k) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (l) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/175/43/2017/F

F. No. 8(43)/2017/D.P./NPPA-Div.-II
(BALJIT SINGH)

Assistant Director



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 11th May, 2017

ORDER

S.O. 1527(E) In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No.	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company respectively	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	P-Ppi-L capsules	Each hard gelatin capsule contains: Pantoprazole sodium eq. to Pantoprazole 40mg (as gastro resistant tablet) Levosulpiride 75mg (as uncoated sustained release tablet)	1 Capsule	M/s Akums Drugs & Pharmaceuticals Ltd./ M/s Blue Cross Lab. Pvt. Ltd.	8.00

Note:

- The manufacturers of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in



paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.

- (d) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (e) The above mentioned retail price is applicable only to the individual manufacturers / marketeers as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
- (f) The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (h) Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand(s) superseded.

PN/176/44/2017/F

F. No. 8(44)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 11th May, 2017

ORDER

S.O. 1525 (E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide letters no. 31015/99/2016-PI.I dated 05.04.2017 passed by the Department of Pharmaceuticals and in exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 3431(E), dated 10th November, 2016 at (Sl. No. 17) & S.O. 1039(E) dated 1st April, 2017 at (Sl. No. 208) regarding formulation packs mentioned in the table in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Dicyclomine	Injection 10 mg/ml (1ML & 2 ML Pack)	1 ML	3.01
2.	Dicyclomine	Injection 10 mg/ml (10ML & 30 ML Pack)	1 ML	1.95

Note:

- All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.



- (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/177/45/2017/F

F. No. 8(45)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 11th May, 2017

ORDER

S.O. 1526(E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide letters no. 31015/20/2015-PI.I dated 30.08.2016 (Erythromycin Estolate Tablet 250mg & 500mg, Erythromycin Estolate Syrup 125mg/5ml & Chloroquine Phosphate Injection 40mg/ml) passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S. O. 834(E) dated 25th March, 2015 at (Sl. No. 4, 5, 3 & 1) & No. S.O. 644(E) dated 2nd March, 2016 at (Sl. No. 205, 206, 204 & 115) (Erythromycin Estolate Tablet 250mg & 500mg, Erythromycin Estolate Syrup 125mg/5ml & Chloroquine Phosphate Injection 40mg/ml) regarding formulation packs mentioned in the table in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1	Erythromycin Estolate	Tablet 250mg	1 Tablet	3.02
2	Erythromycin Estolate	Tablet 500mg	1 Tablet	5.86
3	Erythromycin Estolate	Syrup 125 mg / 5 ml	1 ML	0.53
4	Chloroquine Phosphate	Injection 40 mg / ml (64.5mg eq. to 40mg chloroquine)	1 ML	1.31

Note:

- (a) All manufacturers of formulations, selling the branded or generic or both the versions of formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.



- (b) All the existing manufacturers of above mentioned formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- (c) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (d) The ceiling price for a pack of the formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (g) The manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India

Ministry of Chemicals and Fertilizers

Department of Pharmaceuticals

National Pharmaceutical Pricing Authority

New Delhi, the 15th May, 2017

ORDER

S.O.1569(E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide letters no. 31015/71/2016-PI.I dated 30.01.2017 (Phenobarbitone 30mg Tablet & Sodium Valproate 200mg Tablet); no. 31015/100/2016-PI.I dated 10.03.2017 (Pheniramine 22.75mg/ml Injection) & no. 31015/94/2016-PI.I dated 05.4.2017 (Adrenaline 1mg/ml Injection) respectively passed by the Department of Pharmaceuticals under para 31 of Drugs (Prices Control) Order, 2013 and in exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 2195(E), dated 23rd June, 2016 at (Sl. No. 8 & 9) & S.O. 1039(E) dated 1st April, 2017 at (Sl. No. 502 & 590) (Phenobarbitone 30mg Tablet & Sodium Valproate 200mg Tablet); No. S.O. 3431(E), dated 10th November, 2016 at (Sl. No. 1) & S.O. 1039(E) dated 1st April, 2017 at (Sl. No. 498) (Pheniramine 22.75mg/ml Injection) & No. S.O. 3181(E), dated 7th October, 2016 at (Sl. No. 10) & S.O. 1039(E) dated 1st April, 2017 at (Sl. No. 18) (Adrenaline 1mg/ml Injection) respectively regarding formulation packs mentioned in the table in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Phenobarbitone	Tablet 30mg	1 Tablet	1.16
2.	Sodium Valproate	Tablet 200mg	1 Tablet	2.93
3.	Pheniramine	Injection 22.75 mg/ml (2 ML Pack)	1 ML	1.44
4.	Pheniramine	Injection 22.75 mg/ml (10 ML Pack)	1 ML	1.06
5.	Adrenaline	Injection 1mg/ml	1 ML	14.81

Note:

- (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.



- (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.

- (c) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) The formulation of Sodium Valproate includes combination of Sodium Valproate and Valproic Acid both together corresponding to Sodium Valproate of the stated strength.
- (j) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 21st April, 2017

ORDER

S.O. 1271(E) In implementation of directions given in line with review orders issued by the Department of Pharmaceuticals (DOP) vide letters no. 31015/31/2016-PI.I dated 08.7.2016 & no. 31015/28/2016-PI.I dated 22.7.2016 (Clotrimazole Cream 1%); no. 31015/42/2016-PI.I dated 14.9.2016 (Ceftriaxone Powder for Injection 1gm) & no. 31015/20/2016-PI.I dated 04.7.2016 (Erythropoietin Injection 2000IU/ml & 10000IU/ml) respectively passed by the Department of Pharmaceuticals and in exercise of the powers conferred by paragraphs 4, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1687(E), dated 9th May, 2016 at (Sl. No. 24) & S.O. 1039(E) dated 1st April, 2017 at (Sl. No. 171) (Clotrimazole Cream 1%); No. S.O. 1686(E) dated 9th May, 2016 at (Sl. No. 3) & S.O. 1039(E) dated 1st April, 2017 at (Sl. No. 129) (Ceftriaxone Powder for Injection 1gm) & No. S.O. 1404(E) dated 12th April, 2016 at (Sl. No. 24 & 25) & S.O. 1039(E) dated 1st April, 2017 at (Sl. No. 241 & 240) (Erythropoietin Injection 2000IU/ml & 10000IU/ml) respectively regarding formulation pack mentioned in the table in so far as it relates to formulation pack mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulation specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Clotrimazole	Cream 1%	1 GM	2.49
2.	Ceftriaxone	Powder for Injection 1gm	Each Pack	48.74
3.	Erythropoietin	Injection 2000 IU/ml	Each Pack	582.98
4.	Erythropoietin	Injection 10000 IU/ml	Each Pack	2461.35

Note:

- (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.



- (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- (c) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/176/44/2017/F

F. No. 8(44)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 21st April, 2017

ORDER

S.O. 1272(E) In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No.	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company respectively	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Monocef-SB 125mg Injection	Each vial contains: Ceftriaxone Sodium equivalent to Ceftriaxone 125mg, Sulbactam Sodium equivalent to Sulbactam 62.5mg	Per Vial	M/s Aristo Laboratories Pvt. Ltd. / M/s Aristo Pharmaceuticals Pvt. Ltd.	32.28

Note:

- The manufacturers of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.



- (e) The above mentioned retail price is applicable only to the individual manufacturers / marketeers as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
- (f) The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (h) Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand(s) superseded.

PN/176/44/2017/F

F. No. 8(44)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 24th May, 2017

ORDER

SO. 1689(E) In exercise of the powers conferred by paragraphs 5, 11 and 15 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S. O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA), hereby fixes, the price as specified in column (6) of the table herein below as the retail price, exclusive of local taxes, if any, in relation to the formulation specified in the corresponding entry in column (2) of the said Table with the strength, unit and name of manufacturer & marketing company respectively, as specified in the corresponding entries in columns (3), (4) and (5) thereof;

Table

Sl. No.	Name of the Scheduled Formulation / Brand Name	Strength	Unit	Manufacturer & Marketing Company respectively	Retail Price (Rs.)
(1)	(2)	(3)	(4)	(5)	(6)
1.	Telmisartan + Metoprolol ER Tablet (Telmijub Beta 25)	Each film coated bilayered tablet contains: Telmisartan 40mg Metoprolol succinate eq. to Metoprolol Tartrate 25mg (as extended release)	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Jubilant Life Sciences Limited	7.95
2.	Telmisartan + Metoprolol ER Tablet (Telmijub Beta 50)	Each film coated bilayered tablet contains: Telmisartan 40mg Metoprolol succinate eq. to Metoprolol Tartrate 50mg (as extended release)	1 Tablet	M/s Pure and Cure Healthcare Pvt. Ltd./ M/s Jubilant Life Sciences Limited	9.55
3.	Glimepiride + Voglibose + Metformin SR Tablet	Each uncoated bilayered tablet contains: Glimepiride 1mg	10 Tablets	M/s Windlas Biotech Ltd./M/s Glenmark Pharmaceuticals Ltd.	71.43



	Voglibose 0.2mg Metformin HCL 500mg		
--	--	--	--

		(as sustained released form)			
4.	Glimepiride + Voglibose + Metformin SR Tablet	Each uncoated bilayered tablet contains: Glimepiride 2mg Voglibose 0.2mg Metformin HCL 500mg (as sustained released form)	10 Tablets	M/s Windlas Biotech Ltd./M/s Glenmark Pharmaceuticals Ltd.	90.48
5.	Telmisartan + Chlorthalidone Tablet (Telpres CT 80)	Each uncoated bilayered tablet contains: Telmisartan 80mg Chlorthalidone 12.5mg	1 Tablet	M/s Windlas Biotech Ltd./M/s Abbott Healthcare Pvt. Ltd.	7.00
6.	Diclofenac Diethylamine + Linseed Oil + Methyl Salicylate + Menthol Gel (DICLOTAL+ Gel)	Each gm contains: Diclofenac Diethylamine 1.16% w/w (eq. to diclofenac Sodium 1% w/w) Linseed Oil 3% w/w Methyl Salicylate 10% w/w Menthol 5% w/w	1 GM	M/s The Madras Pharmaceuticals /M/s Blue Cross Lab. Pvt. Ltd.	2.15
7.	Rozuplatt 10 Capsules	Each hard gelatine capsule contains: Rosuvastatin calcium eq. to Rosuvastatin 10mg (As pellets) Clopidogrel Bisulphate eq. to Clopidogrel 75mg (As pellets)	1 Capsule	M/s Torrent Pharmaceuticals Ltd./ M/s Synokem Pharmaceuticals Ltd.	13.94

Note:

- The manufacturers of above mentioned formulations i.e. "new drug" under paragraph 2(u) of the DPCO, 2013 shall fix the retail price as specified in column (6) of the table hereinabove.
- The manufacturers may add local taxes only if they have paid actually or it is payable to the Government on the retail price mentioned in column (6) of the above said table.
- The retail price for a pack of the aforesaid formulation shall be arrived at by the concerned manufacturers in accordance with the retail price specified in column (6) of the above table as per provisions contained in paragraph 11 of the DPCO, 2013. The manufacturers shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.

- (e) The above mentioned retail price is applicable only to the individual manufacturers / marketeers as mentioned above i.e. who have applied for the same by submitting Form-I for price fixation / revision as stipulated under DPCO, 2013 and subject to fulfillment of all the applicable statutory requirements as laid down by the Govt. under relevant statutes/ rules, including manufacturing license permission from the Competent Authority i.e. the Central/State Licensing Authority, as may be applicable, by the concerned manufacturers/marketing companies.
- (f) The concerned manufacturers of above said formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of product in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Manufacturers, in case intending to discontinue above said formulations, shall furnish information to the NPPA, in respect of discontinuation of the production and / or import of above said formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (g) In case the retail price of any of the aforesaid formulations is not complied with, as per instant price notification and notes specified hereinabove, then the concerned manufacturer/marketing company shall be liable to deposit the overcharged amount along with the interest thereon under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955.
- (h) Consequent to the issue of retail price of the aforesaid formulations as specified in column (2) of the above mentioned table in this notification, the price order(s) if any, issued for concerned manufacturer / marketer prior to the above said date of notification, stand(s) superseded.

PN/177/45/2017/F

F. No. 8(45)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 24th May, 2017

ORDER

S. O. 1688(E) In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1040(E) dated 1st April, 2017 and S.O. 1090(E) dated 6th April, 2017 in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Morphine	Injection 10mg/ml	1 ML	22.47
2.	Morphine	Tablet 10mg	1 Tablet	5.04
3.	Glucose	Injection 10%	Each Pack (500 ML)	26.58
4.	Glucose	Injection 10%	Each Pack (1000 ML)	24.43
5.	DPT Vaccine		0.5 ML	12.85
6.	Hepatitis B Vaccine		1 ML	71.06
7.	Snake venom antiserum - Lyophilized polyvalent		10 ML Pack	527.21
8.	Heparin	Injection 5000 IU/ml	1 ML	36.73



9.	IUD containing Copper	As Licensed	1 IUD	260.87
10.	Rifampicin	Tablet 150mg	1 Tablet	1.53
11.	Fluconazole	Capsule 150mg	1 Capsule	17.55

Note:

- (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- (c) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.



- (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/177/45/2017/F

F. No. 8(45)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)
Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 24th May, 2017

ORDER

S.O. 1687(E) In exercise of the powers conferred by paragraphs 4, 5, 6, 10, 11, 14, 15, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Morphine	Injection 15mg/ml	1 ML	28.04
2.	Sodium Valproate	CR Tablet 500 mg	1 Tablet	8.82
3.	Sodium Valproate	CR Tablet 300 mg	1 Tablet	5.73
4.	Coagulation factor VIII	Powder for Injection 500 IU	Each Pack	8,316.70
5.	Spironolactone	Tablet 50 mg	1 Tablet	3.60
6.	Diclofenac	Capsule 50mg	1 Capsule	0.58
7.	Ibuprofen	Capsule 400mg	1 Capsule	1.00
8.	Clotrimazole	Lotion 1%	1 ML	3.39
9.	Permethrin	Cream 1%	1 GM	1.52
10.	Permethrin	Gel 5%	1 GM	1.38
11.	Permethrin	Lotion 5%	1 ML	0.92
12.	Clomiphene	Capsule 50mg	1 Capsule	28.97
13.	Paracetamol	Injection 150mg/ml	Each Pack	2.90

			(0.5 ML)	
14.	Paracetamol	Injection 150mg/ml	Each Pack (1 ML)	3.97
15.	Paracetamol	Injection 150mg/ml	Each Pack (3 ML)	8.24
16.	Paracetamol	Injection 150mg/ml	Each Pack (4 ML)	10.37
17.	Paracetamol	Injection 150mg/ml	Each Pack (5 ML)	12.51
18.	Paracetamol	Injection 150mg/ml	Each Pack (7 ML)	16.78
19.	DPT + Hib + Hep B Vaccine		0.1 ML	72.874

Note:

- (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- (c) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form- V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.



- (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/177/45/2017/F

F. No. 8(45)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 27th April, 2017

ORDER

S.O. 1333(E) In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority (hereinafter referred as NPPA) hereby fixes the prices as specified in column (5) of the table herein below as ceiling price exclusive of local tax applicable, if any, in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.	Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)
(1)	(2)	(3)	(4)	(5)
1.	Vancomycin	Powder for Injection 250mg	Each Pack	201.20
2.	Etoposide	Capsule 50mg	1 Capsule	51.44
3.	Noradrenaline	Injection 2mg/ml	1ML	24.38
4.	Budesonide	Nasal Spray 100mcg/dose	1 Dose	0.85
5.	Budesonide	Nasal Spray 50mcg/dose	1 Dose	0.96
6.	5-aminosalicylic Acid	Suppository 500mg Retention Enema	1 Suppository	15.99
7.	Isosorbide-5-mononitrate	SR Capsule 60mg	1 Capsule	3.29
8.	Isosorbide-5-mononitrate	SR Capsule 30mg	1 Capsule	3.32



Note :

- (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- (c) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) Consequent to the issue of ceiling price of such formulation as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/176/44/2017/F

F. No. 8(44)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director



(Published in Part II, Section 3, Sub-section (ii) of the Gazette of India, Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
National Pharmaceutical Pricing Authority

New Delhi, the 27th April, 2017

ORDER

S.O. 1334(E) In exercise of the powers conferred by paragraphs 4, 6, 10, 11, 14, 16, 17 and 18 of the Drugs (Prices Control) Order, 2013, read with S.O. 1394(E) dated the 30th May, 2013 and S.O. 701(E) dated 10th March, 2016 issued by the Government of India in the Ministry of Chemicals and Fertilizers, and in supersession of the Order of the Government of India in the Ministry of Chemicals and Fertilizers (National Pharmaceutical Pricing Authority) No. S.O. 1040(E), dated 1st April, 2017, in so far as it relates to formulation packs mentioned in the table below, except in respect of things done or omitted to be done before such supersession, the National Pharmaceutical Pricing Authority, hereby fixes the price as specified in column

(5) of the table herein below as ceiling price exclusive of local tax applicable, if any in respect of the Scheduled formulations specified in the corresponding entry in column (2) of the said Table with the dosage form & strength and unit specified respectively in the corresponding entries in columns (3) and (4) thereof:

TABLE

Sl. No.		Name of the Scheduled Formulation	Dosage form & Strength	Unit	Ceiling Price (Rs.)
(1)		(2)	(3)	(4)	(5)
1.		Snake venom antiserum - Soluble/liquid polyvalent	Injection	10 ML Pack	351.44
2.		Heparin	Injection 1000 IU/ml	1 ML	14.80
3.		Glyceryl Trinitrate	Injection 5 mg/ml	1 ML	6.21
4.		Digoxin	Injection 0.25 mg/ml	1 ML	3.16
5.		Hormone Releasing IUD	Contains 52 mg of Levonorgestrel	1 IUD	3,509.95



Note:

- (a) All manufacturers of scheduled formulations, selling the branded or generic or both the versions of scheduled formulations at a price higher than the ceiling price (plus local taxes as applicable) so fixed and notified by the Government, shall revise the prices of all such formulations downward not exceeding the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any.
- (b) All the existing manufacturers of above mentioned scheduled formulations having MRP lower than the ceiling price specified in column (5) in the above table plus local taxes as applicable, if any, shall continue to maintain the existing MRP in accordance with paragraph 13 (2) of the DPCO, 2013.
- (c) The manufacturers may add local taxes only if they have paid actually or if it is payable to the Government on the ceiling price mentioned in column (5) of the above said table.
- (d) The ceiling price for a pack of the scheduled formulation shall be arrived at by the concerned manufacturer in accordance with the ceiling price specified in column (5) of the above table as per provisions contained in paragraph 11 of the Drugs (Prices Control) Order, 2013. The manufacturer shall issue a price list in Form-V from date of Notification as per paragraph 24 of the DPCO, 2013 to NPPA through IPDMS and submit a copy to State Drug Controller and dealers.
- (e) As per para 24(4) of DPCO 2013, every retailer and dealer shall display price list and the supplementary price list, if any, as furnished by the manufacturer, on a conspicuous part of the premises where he carries on business in a manner so as to be easily accessible to any person wishing to consult the same.
- (f) Where an existing manufacturer of scheduled formulation with dosage or strength or both as specified in the above table launches a new drug as per paragraph 2 (u) of the DPCO, 2013 such existing manufacturer shall apply for prior price approval of such new drug to the NPPA in Form I as specified under Schedule-II of the DPCO, 2013.
- (g) The manufacturers of above said scheduled formulations shall furnish quarterly return to the NPPA, in respect of production / import and sale of scheduled formulations in Form-III of Schedule-II of the DPCO, 2013 through IPDMS. Any manufacturer intending to discontinue production of above said scheduled formulation shall furnish information to the NPPA, in respect of discontinuation of production and / or import of scheduled formulation in Form-IV of Schedule-II of the DPCO, 2013 at least six months prior to the intended date of discontinuation.
- (h) The manufacturers not complying with the ceiling price and notes specified hereinabove shall be liable to deposit the overcharged amount along with interest thereon under the provisions of the Drugs (Prices Control) Order, 2013 read with Essential Commodities Act, 1955.
- (i) Consequent to the issue of ceiling prices of such formulations as specified in column (2) of the above table in this notification, the price order(s) fixing ceiling or retail price, if any, issued prior to the above said date of notification, stand(s) superseded.

PN/176/44/2017/F

F. No. 8(44)/2017/D.P./NPPA-Div.-II

(BALJIT SINGH)
Assistant Director